

## **REMARKS**

### **A. Status of the Claims**

Claims 9-18 were pending at the time of the Action. Claim 9 has been amended to correct a typographical error. New claims 19-21 have been added. Thus, claims 9-21 are currently pending. Because the amendment to claim 9 merely corrected a typographical error recognized by the examiner (*see* Action, p. 4) and the new claims merely recite a narrower subset of the antioxidants A and antioxidants B recited in claim 9, any new grounds for rejection cannot be based on Applicant's amendment. Thus, it would be improper for a subsequent Office Action to be made final if it includes any new grounds for rejection. *See* MPEP § 706.07(a).

### **B. Oath/Declaration**

The Action asserts that a new oath or declaration is required because the declaration as filed in the application is not in the English language. This assertion is incorrect. The present application is a U.S. nationalization of a PCT application under 35 U.S.C. § 371, and a declaration in accordance with PCT Rule 4.17(iv) was provided. 37 C.F.R. § 1.69(b) states that in a U.S. nationalization of a PCT application under 35 U.S.C. § 371, a translation is not required of a declaration provided in accordance with PCT Rule 4.17(iv).

### **C. The Claims Satisfy the Requirements of 35 U.S.C. § 112, ¶ 1 and 2**

The Action rejects claims 9-18 under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement, and under 35 U.S.C. § 112, second paragraph, as being indefinite. The Action's asserted basis for both rejections is that the specification does not define the chemical names for the antioxidants represented by the abbreviations NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH. Applicant traverses these rejections.

A proper evaluation of claims 9-18 under the second paragraph of 35 U.S.C. § 112 requires that the claims be read in light of the specification as interpreted by one of ordinary skill

in the art. *North Am. Vaccine, Inc. v. American Cyanamid Co.*, 7 F.3d 1571, 1579, 28 USPQ 2d 1333, 1339 (Fed. Cir. 1993). Whether a claim satisfies the written description requirement of the first paragraph of 35 U.S.C. § 112 is likewise determined from the perspective of a person of ordinary skill in the art. To satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventors had possession of the claimed invention. *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563 (Fed. Cir. 1991). The current claims satisfy the requirements of 35 U.S.C. § 112, first and second paragraphs.

### **1. *Well-Known Terms of Art Do Not Require Detailed Definitions***

Use of well-known terms of art in the specification without detailed definitions does not render claims utilizing that same language indefinite. *W.L. Gore & Assoc., Inc. v. Garlock, Inc.*, 721 F.2d 1540, 1556-58 (Fed. Cir. 1983). Claims may, therefore, make use of the language understood by those of skill in the art without additional, detailed definitions in the written description. *Id.* As described in more detail below, the terms NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH are well-known terms that are readily understood by those in the art. Thus, these terms do not require detailed definitions in the specification.

### **2. *The Terms NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH Would Be Understood by Any Person Who Has Taken an Entry-Level Biochemistry Course***

The Action clearly failed to examine the claims from the perspective of a person of ordinary skill in the art, as the terms NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH are well-known terms that are readily understood by those in the art. In fact, these terms would even be understood by those who have only taken an entry-level biochemistry course.

NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH are commonly used abbreviations for nicotinamide adenine dinucleotide, reduced form; nicotinamide adenine

dinucleotide phosphate, reduced form; flavin adenine dinucleotide, reduced form; flavin mononucleotide, reduced form; flavin adenine dinucleotide, radical form; and flavin mononucleotide, radical form; respectively. It is readily apparent from standard biochemistry text books that these abbreviations are commonly used and understood in the art. For example, attached as Exhibit B to the Declaration of Dr. Pfannhauser (“Pfannhauser Declaration”) (attached as Appendix A to this paper) is a table entitled “Some Common Biochemical Abbreviations” from Voet & Voet, BIOCHEMISTRY, 2d Ed., (John Wiley & Sons, Inc., 1995), which shows that NADH, NADPH, FADH<sub>2</sub>, FADH, and FMN are well-known abbreviations in biochemistry. In fact, such abbreviations are used preferentially in Voet & Voet. If a person were to look up, for example, “nicotinamide adenine dinucleotide, reduced form” in the index of Voet & Voet that person would be directed to “*see NADH*.” The same is true of NADPH, FADH<sub>2</sub>, FADH, and FMN. A highlighted copy of the relevant pages of the index is attached as Exhibit C to the Pfannhauser Declaration. Although the reduced and radical forms of FMN are not listed in the index, the terms FMNH<sub>2</sub> and FMNH are used in Voet & Voet at, for example, page 575 (Exhibit D to the Pfannhauser Declaration). Another undergraduate-level biochemistry text, Streyer, BIOCHEMISTRY, 3d Ed. (W.H. Freeman and Co., 1988) contains a table entitled “Common Abbreviations in Biochemistry,” which lists NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FAD, and FMN. A copy of this table is attached as Exhibit E to the Pfannhauser Declaration.

NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH are components of energy metabolism pathways (Pfannhauser Declaration, para. 5). NADH and FADH<sub>2</sub> are the major electron carriers in the oxidation of fuel molecules (Pfannhauser Declaration, para. 10). FAD may be fully reduced to FADH<sub>2</sub> or half-reduced to FADH (Pfannhauser Declaration, para. 10). NADPH is the major electron donor in reductive biosynthesis (Pfannhauser Declaration, para. 10). FMN is a component of Complex I of the mitochondrial electron transport chain

(Pfannhauser Declaration, para. 10). FMNH<sub>2</sub> is the reduced form of FMN and FMNH is the radical form of FMN (Pfannhauser Declaration, para. 10).

As stated in the Pfannhauser Declaration, energy metabolism pathways are learned by university students in their entry-level biochemistry courses (Pfannhauser Declaration, para. 5). Thus, even first-year university students who have taken an entry-level biochemistry course would readily understand the meaning of the terms NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH.

The Pfannhauser Declaration further notes that is clear from the present specification that NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH are described in the context of energy metabolism and electron transfer (Pfannhauser Declaration, para. 10). The Pfannhauser Declaration concludes that in view of the description of NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH in the present specification and the common use of these well-known terms in the biochemistry field, there is no question that scientists (and even students) in this field would readily understand the meaning of NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH as recited in the present claims and specification. (Pfannhauser Declaration, para. 11).

### **3. *The Examiner Has Not Met His Burden***

In rejecting a claim under the written description requirement, the Examiner has the initial burden of presenting evidence or reasons why a person skilled in the art would not recognize in an Applicant's disclosure a description of the invention defined in the claims. *In re Wertheim*, 541 F.2d 257, 262 (CCPA 1976). Accordingly, the Examiner is required: (1) to set forth the claim limitation not described; and (2) to provide reasons why a person skilled in the art would not have recognized the description of the limitation in view of the disclosure of the application as filed. *Interim Guidelines for the Examination of Patent Applications Under 35*

*U.S.C. 112, Paragraph 1.* In making an indefiniteness rejection, the Examiner is required to provide an analysis as to why the claim is “vague and indefinite.” MPEP § 2173.02.

The only alleged reasoning provided to support the written description and definiteness rejections is that the abbreviations render the claims “totally unsearchable” because a person of ordinary skill in the art “would have no idea what one is searching and looking for.” (Action, p. 3; *see also* p. 4). It is unclear why the Examiner considers the terms NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH “totally unsearchable.” To demonstrate that these terms are in fact searchable, Applicant typed the search term “NADH” into the PubMed database on September 11, 2006. The search returned 39,521 articles. To obtain a more manageable number of results, the search was then limited to only those articles published in 2002 and in which “NADH” occurred in the title. With these limitations the search returned 124 articles. A copy of the search results is attached as Appendix B. Numerous results were also obtained when Applicant searched the PubMed database for any of the terms NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, or FMNH. The Action’s unsupported assertion that the claims are “totally unsearchable” is clearly inaccurate. Thus, the Action did not meet its burden of establishing that the claims do not satisfy the definiteness and written description requirements.

#### **4. Conclusion**

For the reasons set forth above, the present claims are definite and supported by adequate written description. Applicant, therefore, requests the withdrawal of these rejections.

#### **D. Claim Objections**

Claim 10 is objected to under 37 C.F.R. § 1.75(c) as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant traverses this objection.


An antioxidant is a compound that inhibits oxidation by binding free oxygen radicals. As recited in claim 9, antioxidant A is NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, or FMNH; and antioxidant B is chlorophyll and/or a reduced ferredoxin. An “oxygen-sequestering substance” is a substance, such as an oil, that reduces, or largely prevents, any contact between antioxidant A and oxygen (Specification, p. 6, ln. 1-22). As described in the specification, an “oxygen-sequestering substance” protects antioxidant A by preventing the *contact* of antioxidant A with oxygen, whereas another antioxidant (i.e., antioxidant C) protects antioxidant A by *reducing oxygen* before the oxygen can react with antioxidant A (p. 6, ln. 23-32). Thus, claim 10 is a proper dependent claim because it references claim 9 and specifies a further limitation, namely that the composition of claim 9 further comprise an oxygen-sequestering substance, which is not the same substance as antioxidant A or antioxidant B as defined in current claim 9.

#### E. Conclusion

Applicant believes this to be a complete reply to the Office Action dated June 21, 2006, and respectfully requests favorable consideration of the claims in view of the amendments and statements contained herein.

The Examiner is invited to contact the undersigned attorney with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Travis M. Wohlers  
Reg. No. 57,423  
Attorney for Applicant

(Customer No. 32425)  
FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
512.536.5654 (voice)  
512.536.4598 (fax)

Date: September 15, 2006

## APPENDIX A

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Behzad SADEGHI *et al.*

Serial No.: 10/535,330

Group Art Unit: 1714

Filed: May 18, 2005

Examiner: Anthony, Joseph David

For: NADH/NADPH-CONTAINING COMPOUND

Atty. Dkt. No.: SONN:073US

**DECLARATION OF WERNER PFANNHAUSER, PH.D.**

I, Werner Pfannhauser, hereby declare as follows:

1. I am an Austrian citizen residing at Kreuzgasse 79, A - 1180 Vienna, Austria.
2. I am currently the head of the Institute of Food Chemistry and Technology at the Technical University of Graz in Graz, Austria. I have extensive experience in the fields of chemistry and biochemistry. A copy of my *Curriculum Vitae* is attached as Exhibit A.
3. I have reviewed the specification of the above-referenced application, the currently pending claims, the amended set of claims, and the Office Action dated June 21, 2006.
4. I understand that the Examiner rejected claims 9-18 as being indefinite and lacking adequate written description. I understand that the Examiner asserts that because the specification does not define the chemical names for the abbreviations NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH, a person of ordinary skill in the art would not understand the meaning of these terms. I do not find this to be the case.

5. The terms NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH are well-known in the field of biochemistry as they are components of energy metabolism pathways. In my experience, both as a student and as a professor, energy metabolism pathways (e.g., glycolysis, citric acid cycle, and oxidative phosphorylation) are taught to university students in their entry-level biochemistry courses. As evidence of this, I have attached as Exhibits B-G pages from two general biochemistry text books: Voet & Voet, BIOCHEMISTRY, 2d Ed., (John Wiley & Sons, Inc., 1995) and Stryer, BIOCHEMISTRY, 3d Ed. (W.H. Freeman and Co., 1988).

6. Exhibit B is a table entitled "Some Common Biochemical Abbreviations" from Voet & Voet, which shows that NADH, NADPH, FADH<sub>2</sub>, FADH, and FMN are well-known abbreviations in biochemistry. Exhibit C contains pages from the index of Voet and Voet listing NADH, NADPH, FADH<sub>2</sub>, FADH, and FMN. Although the reduced and radical forms of FMN are not listed in the index, FMNH<sub>2</sub> and FMNH are described in Voet & Voet at, for example, page 575 (Exhibit D). Exhibit E is a table from the Stryer text book entitled "Common Abbreviations in Biochemistry," which lists NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FAD, and FMN.

7. Exhibit F contains pages 785 to 788 from Voet & Voet and provides a summary of the major energy metabolism pathways. NADH, NADPH, and FADH<sub>2</sub> are specifically mentioned on these pages. I also note that they are referred to as "NADH," "NADPH," and "FADH<sub>2</sub>" and not as "nicotinamide adenine dinucleotide, reduced form," "nicotinamide adenine dinucleotide phosphate, reduced form," and "flavin adenine dinucleotide, reduced form." FADH is described on pages 400-401 of Voet & Voet (Exhibit G). FMNH<sub>2</sub> and FMNH are described on page 575 of Voet & Voet (Exhibit D).

8. Accordingly, anyone who has taken an entry-level biochemistry course would readily understand the meaning of the terms NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH. Of course, scientists who conduct research in this field would also readily understand the meaning of these terms.

9. Although the compounds NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH may also be referred to as nicotinamide adenine dinucleotide, reduced form; nicotinamide adenine dinucleotide phosphate, reduced form; flavin adenine dinucleotide, reduced form; flavin mononucleotide, reduced form; flavin adenine dinucleotide, radical form; and flavin mononucleotide, radical form, respectively; it is has been my experience from the scientific literature and from communications with my colleagues and students that NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH are the more commonly used terms. The preferred use of the terms NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH is evident in Voet & Voet. For example, if a person looks up "nicotinamide adenine dinucleotide, reduced form" in the index of Voet & Voet (attached as Exhibit D) that person would be directed to "see NADH." The same is true of NADPH, FADH<sub>2</sub>, FADH, and FMN.


10. From my review of the present specification, it is clear that NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH are described in the context of energy metabolism and electron transfer. As explained in the preceding paragraphs, it is well-known that NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH are components of energy metabolism pathways (see also Exhibits B-G). In particular, it is well-known that NADH and FADH<sub>2</sub> are the major electron carriers in the oxidation of fuel molecules, and that FAD may be fully reduced to FADH<sub>2</sub> or half-reduced to FADH. NADPH is the major electron donor in reductive biosynthesis. FMN is a

component of Complex I of the mitochondrial electron transport chain and FMNH<sub>2</sub> is the reduced form of FMN and FMNH is the radical form of FMN.

11. In view of the description of NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH in the present specification and the common use of these well-known terms in the biochemistry field, there is no question that scientists (and even students) in this field would readily understand the meaning of NADH, NADPH, FADH<sub>2</sub>, FMNH<sub>2</sub>, FADH, and FMNH as recited in the present claims and specification.

12. I declare that all statements made of my knowledge are true and all statements made on the information are believed to be true; and, further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issued thereupon.

Date: 13.9.2006



Werner Pfannhauser, Ph.D.

## **EXHIBIT A**

**O.Univ.Prof. Dr. Werner Pfannhauser**  
**Institute of Food Chemistry and –technology, University of Technology Graz**  
**A- 8010 Graz, Petersgasse 12/2**  
**Private : A - 8081 Heiligenkreuz am Waasen**  
**A - 1180 Wien, Kreuzgasse 79**

## C U R R I C U L U M

7.6.1940 born in Vienna / Austria  
2.6.1959 Matura BG XVIII Vienna  
1.9.1963 - 31.8.1965 Employee (research contract) at Wienerberger Ziegelfabriks- und Baugesellschaft, Vienna, working at TGM (Higher technical School)  
1.9.1963 - 31.8.1969 Assistsant at TGM (Higher Technical School), Department of Silica Techniques  
1969 Grant for gifted students  
1969 - 1971 Thesis at Institute of Analytical Chemistry (Univ.Prof. F. Hecht) University of Vienna  
8.7.1971 Promotion  
24.1.1971 Titel Engeneer (Ing)  
16.8.1971 -  
31.8.1993 Chemist, Senior Scientist (1974) and Vizedirector (1981) of Forschungsinstitut der Ernährungswirtschaft (Research Institute of the Food Industry), Vienna  
1978 Research Grant of the City of Vienna  
1979 - 1996 Secretary of the Federation of European Chemical Societies (FECS) Working Party of Food Chemistry (WPFC), now renamed Division of Food Chemistry  
since 1994 Austrian Delegate in FECS / FCD  
since 1984 Board Member of the Austrian Society of Analytical Chemistry (ASAC),  
since 1991 Vice President of ASAC  
7.12.1988 Habilitation for Analytical Chemistry ar Technical University of Vienna  
since 1992 Chairman of the Working Party of Food Chemistry of the Austrian Chemical Society (GÖCh)  
1.10.1993 Appointed as a Full Professor of Food Chemistry at the Technical University of Graz, Institute of Bio- and Food Chemistry  
1995 - 1998 Scientific director of Lebensmittelversuchsanstalt and Forschungsinstitut der Ernährungswirtschaft, Vienna  
September 1996 Editor of Ernährung / nutrition  
1996 –2000 President of the Austrian Society of Nutrition (ÖGE)  
11/2000 Head of the newly founded Institute of Food Chemistry and - technology

Private:

married with Dkfm. Gertraud Pfannhauser, born Gruber, 5 sons;  
Owner of a private consulting agency in Vienna

Distinctions:

1988 : Gold Medal of the Italian Society of Flavour Research (Societa Scienze Aromatizzanti SSA)

1994 : Silver Medal of Merit of The City of Vienna

# **PUBLIKATIONSLISTE**

**O. Univ. Prof. Dr. Werner Pfannhauser**

**Institut für Lebensmittelchemie und -technologie  
TU-Graz  
8010 Graz, Petersgasse 12/II**

## 1991

W.Pfannhauser  
Die Schwermetallbelastung der österreichischen Nahrung im internationalen Vergleich  
Ernährungsforschung 36, 13, (1991)

W.Pfannhauser  
Spurenelemente in der Nahrung  
Österreichische Apotheker Zeitung 45, (13) 269 (1991)

## 1992

W. Pfannhauser  
Das essentielle Spurenelement Selen : Bedeutung, Wirkung und Vorkommen in der Nahrung. I. Essentialität, Funktion und Aufnahme. Selengehalte in Böden, Pflanzen und Tieren.  
Ernährung / nutrition 16, (9), 506 (1992)

Das essentielle Spurenelement Selen : Bedeutung, Wirkung und Vorkommen in der Nahrung. II. Selen und die Immunlage des Organismus  
Ernährung / nutrition 16, (10) 567 (1992)

Das essentielle Spurenelement Selen : Bedeutung, Wirkung und Vorkommen in der Nahrung. III. Selenversorgung und Aufnahmedaten aus Österreich im Vergleich mit Daten aus anderen Ländern. Schlußfolgerungen.  
Ernährung / nutrition 16, (11) 642 (1992)

## 1993

W.Pfannhauser  
Volatiles formed during Extrusion Cooking of Cereals  
Flavour and Frangrance Journal 8, 109, (1993)

W.Pfannhauser  
Selenaufnahme in Europa  
Proceedings „Defizit und Überschuß an Mengen- und Spurenelementen in der Ernährung. S 79 -94  
Jena 1994

## 1994

W.Pfannhauser  
Versorgungsstatus mit dem essentiellen Spurenelement Selen in Österreich  
Lebensmittelchemie 48, 123 (1994)

G. Cvirn, M. Murkovic, W. Pfannhauser  
Zearalenon und Deoxynivalenol in österreichischem Getreide  
Mitt. Hygiene (Bern) 85, 728 (1994)

H. Löw, M. Murkovic, W. Pfannhauser  
Bestimmung von 2-Amino-3-methylimidazol[4,5-f]quinoolin (IQ) in Fleischprodukten  
Proceedings Österreichische Chemietage 1994 Graz

Strigl A.W., Leitner E. u. Pfannhauser W.  
Vorkommen und Analyse der Farbstoffe der Schwarzen Apfelbeere (Aronia  
melanocarpa)  
8. Österreichische Chemikertage Graz, Proceedings, S. 97. (1994)

## 1995

W. Pfannhauser  
Der Versorgungsstatus mit dem essentiellen Spurenelement Selen in Österreich  
Lebensmittel- und Biotechnologie 1995, 17

A.W. Strigl, E. Leitner, W. Pfannhauser  
Zur Bestimmung des „Farbwertes“ von Früchten und Beeren am Beispiel der  
Schwarzen Apfelbeere (Aronia melanocarpa)  
Lebensmittelchemie 49, 03 (1995)

M. Wilplinger, I. Schönsleben, W. Pfannhauser  
Chrom in österreichischen Lebensmitteln  
Z. Lebensm. Unters. Forsch. 201, 521 - 523 (1995)

A.W. Strigl, E. Leitner, W. Pfannhauser  
Qualitative und Quantitative Analyse der Anthocyane in Schwarzer Apfelbeere  
(Aronia melanocarpa Michx. Ell.) mittels TLC, HPLC und UV/VIS - Spekrometrie  
Z. Lebensm. Unters. Forsch. 201, 266 (1995)

A.W. Strigl, E. Leitner, W. Pfannhauser  
Die Schwarze Apfelbeere als natürliche Farbstoffquelle  
Deut. Lebensm. Rdsch. 91, 177 (1995)

U. Pechanek, W. Pfannhauser, C. Holler, K. Irsigler, H. Pinscher  
Chemical and physiological aspects of enzyme-modified fibre  
Europ. J. Clin. Nutr. 49, Suppl. 3, 291 - 95 (1995)

Fuchs, A. Krämer-Schafhalter, S. Silhar, M. Kovac, W. Pfannhauser  
Influence of particle size and solvents on anthocyanin extraction of black chokeberry  
(Aronia melanocarpa)  
Current Status and Future Trends in Analytical Food Chemistry  
Proceedings of EURO FOOD CHEM VIII, Vienna, 1995, p.227  
G. Sontag, W. Pfannhauser eds.; ISBN 3-900554-17-X

Fuchs, A. Krämer-Schafhalter, S. Silhar, M. Kovac, W. Pfannhauser  
Reinigung von Anthocyanen aus der Schwarzen Apfelbeere (*Aronia melanocarpa* Nero) über Festphasen  
13. HP-Forum Analytik, Wien, 22.-24.1.1996 (Poster)

Krämer-Schafhalter, H. Fuchs, A. Strigl, S. Silhar, M. Kovac, W. Pfannhauser  
Process Consideration for Anthocyanin Extraction from Black Chokeberry (*Aronia melanocarpa* Ell.)  
Presentation at the International Symposium on Natural Colorants, Acapulco, Mexico, 23.-27.1.1996

Strigl, A. Krämer-Schafhalter, H. Fuchs, M. Scharf, E. Leitner, W. Pfannhauser  
Extraction and Analysis of the Anthocyanins in Black Chokeberry a(*Aronia melanocarpa* MICHX. Ell.)  
Proceedings of the 2nd International Symposium on Natural Colorants, Acapulco, Mexico, 1996

Krämer-Schafhalter, H. Fuchs, S. Silhar, M. Mariassyova, A. Kintlerova, M. Kovac und W. Pfannhauser  
Gewinnung von Destillaten aus der schwarzen Apfelbeere (*Aronia melanocarpa*), Krasny Prcimysl, in prep.

## 1996

Fuchs, A. Kraemer-Schafhalter, S. Silhar, M. Mariassyova, A. Kintlerova, M. Kovac, W. Pfannhauser  
Quality of dye from *Aronia melanocarpa* var. Nero and optimal extraction conditions, Bulletin PV (Bratislava), 35, 101-110 (1996)

M. Wilplinger, I. Schönsleben, W. Pfannhauser  
Versorgungszustand der Österreicher mit dem Spurenelement Chrom  
Z. Lebensm. Unters. Forsch. 203, 207 - 209 (1996)

S. Schlemitz, W. Pfannhauser  
Bestimmung von nitrierten polzyklischen aromatischen Kohlenwasserstoffen in Lebensmitteln mittels gaschromatographischer Analyse.  
(Poster beim Deutschen Lebensmittelchemiker Tag 1995)  
Lebensmittelchemie 50, 21 (1996)

M. Murkovic, A. Hillebrand, J. Winkler, W. Pfannhauser  
Variability of vitamin E content in pumpkin seeds (*Cucurbita pepo* L.)  
Z. Lebensm. Unters. Forsch. 202, 275 - 78 (1996)

S. Schlemitz, W. Pfannhauser  
Monitoring of nitropolycyclic aromatic hydrocarbons in food using gas chromatography  
Z. Lebensm. Unters. Forsch. 203, 61-64 (1996)

B.Siegmund, E.Leitner, H.Siegl, I.Mayer, W.Pfannhauser  
Die Kombination instrumenteller und sensorischer Methoden zur Identifizierung  
aromaaktiver Verbindungen in Fleisch  
Mitt.Hygiene (Bern) 87, 296 - 306 (1996)

B.Siegmund, E.Leitner, I.Mayer, P.Farkas, J. Sadecka, W.Pfannhauser  
Untersuchungen zur Problematik der Extraktion von Aromastoffen mit der simultanen  
Destillation-Extraktion nach Lickens-Nickerson  
Deut. Lebensm. Rdsch. 92, 286 (1996)

H.Fuchs, A. Krämer-Schafhalter, W.Pfannhauser, S. Silhar, M.Mariassiva,  
A.Kintlerova, M.Kovac  
Pigment from Aronia melanocarpa var. Nero and optimum extraction conditions  
Bull. Potravin. Vysk. 35, 101 (1996)

S.Schlemitz, W.Pfannhauser  
Analysis of nitro-PAHs in food matrices by on-line reduction and high performance  
liquid chromatography  
Food Additives and Contaminants 13, 969 - 977 (1996)

B.Siegmund, E.Leitner, I.Mayer, P.Farkas, J.Sadecka, W.Pfannhauser, M.Kovac  
Untersuchungen zur Problematik der Extraktion von Aromastoffen mir der simultanen  
Destillation-Extraktion nach Likens-Nickerson  
Deutsche-Lebensmittel-Rundschau, (1996), 92(9), 286-290.

S. Schlemitz, W. Pfannhauser  
Analysis of nitro-PAHs in food matrices by on-line reduction and high performance  
liquid chromatography  
Food Additives and Contaminants, 8, 969-977, (1996)

Hillebrand, A., Murkovic, M., Winkler, J., und Pfannhauser, W.  
Ein hoher Gehalt an Vitamin E und ungesättigten Fettsäuren als neues Zuchtziel des  
Kürbiszüchters  
Ernährung/Nutrition 20(10):525-527, 1996.

R. van Eckert, P. Rait, W.  
S. Pfannhauser  
Österreichische Datenbank für überempfindliche Personen  
Ernährung/ Nutrition (1996) 20(9):472-473

Response of different gliadin preparations in commercial ELISA-Kits  
R. van Eckert, U. Swaton, W. Pfannhauser  
11<sup>th</sup> Meeting of the Working Group on Prolamin Analysis and Toxicity,  
6.11.-8.11.1996, Tecklenburg, Deutschland (Poster)

Österreichische Datenbank für überempfindliche Personen  
R. van Eckert, R. Rait, W. Pfannhauser  
Internationaler Lebensmittelchemikertag, 12.9.1996, Freiburg im Breisgau,  
Deutschland (Poster)

Österreichische Datenbank für überempfindliche Personen  
R. van Eckert, P. Rait, W. Pfannhauser  
Österreichische Lebensmittelchemiker Tage, 12.9.-13.9.1996, Graz (Poster)

Anthocyanins of *Aronia melanocarpa*: analysis, stability, changes during treatment and storage

A. Krämer-Schafhalter, H. Fuchs, W. Pfannhauser, S. Šilhar, M. Máriássyová, A. Kintlerová, M. Kováč

Proceedings Symposium on Polyphenols and Anthocyanins as Food Colourants and Antioxidants, 15.11.1996, Wien (Poster)

The evaluation of the *Likens-Nickerson*-Extraction for the generation of aroma-extracts demonstrated at a convenient hen-broth, olfaction and electronic nose  
B. Siegmund, E. Leitner, I. Mayer, W. Pfannhauser, P. Farkáš, J. Sádecká J., M. Kováč

3.11.-6.11.1996, Miami, USA (Poster)

Lebensmittelqualität - was ist das ?

W. Pfannhauser

Ernährung / nutrition 95, (1) 1 - 8 (1996)

## 1997

M. Murkovic, D. Wiltschko, W. Pfannhauser

Formation of  $\alpha$ -Tocopherolquinone and  $\alpha$ -Tocopherolquinone Epoxides in Plant Oil Fett / Lipide 99, (5), 165 - 169 (1997)

B. Siegmund, E. Leitner, I. Mayer, W. Pfannhauser, P. Farkas, J. Sádecka, M. Kováč  
5,6-Dihydro-2,4,6-trimethyl-4H-1,3,5-dithiazine - an aroma-active compound formed in course of the Likens-Nickerson extraction

Z. Lebensm. Unters. Forsch. 205, 73 - 75 (1997)

M. Murkovic, M. Gailhofer, W. Steiner, W. Pfannhauser

Formation of zearalenone on wheat contaminated with *Fusarium graminearum* under controlled conditions

Z. Lebensm. Unters. Forsch. A 204 :39-42 (1997)

M. Wilplinger, W. Pfannhauser

Aktueller Versorgungszustand der Österreicher mit dem Spurenelement Chrom  
Ernährung/Nutrition 21 (2), 61-62 (1997)

M. Murkovic, M. Friedrich, W. Pfannhauser

Heterocyclic aromatic amines in fried poultry meat

Z. Lebensm. Unters. Forsch. A 205 347-350 (1997)

S. Schlemitz, W. Pfannhauser  
Supercritical fluid extraction of mononitrated polycyclic aromatic hydrocarbons from tea - Correlation with the PAH concentration  
Z Lebensm Unters Forsch A (1997) [in press]

Krämer-Schafhalter, H. Fuchs, A.W. Strigl, W. Pfannhauser  
Die schwarze Apfelbeere zur Gewinnung von Naturfarbstoffen  
Ernährung/Nutrition, 21 (6), 260-262 (1997)

M. Murkovic, S. Draxl, W. Pfannhauser  
Vitamin B1 in österreichischem Getreide  
Ernährung/Nutrition, 21 (6), 263 265 (1997),

P.Farkaš, J.Sádecká, M.Kovác, B.Siegmund, E.Leitner, W.Pfannhauser  
Key Odourants of Pressure-Cooked Hen Meat  
Food Chemistry, 60,(4), 617 - 621 (1997)

R. van Eckert, P. Rait, W. Pfannhauser  
Österreichische Datenbank für überempfindliche Personen  
Lebensmittelchemie 51, (6) (1997)

Bildung von heterozyklischen aromatischen Aminen in gebratenem Putenfleisch  
M. Murkovic, M. Friedrich, W. Pfannhauser  
HP-Forum Analytik, 21.1.-23.1.1997, Wien (Poster)

Vitamin B1 in österreichischem Getreide  
M. Murkovic, S. Draxl, W. Pfannhauser  
HP-Forum Analytik, 21.1.-23.1.1997, Wien (Poster)

Can erucic acid be used as an indicator for adulteration of pumpkin seed oil with rape seed oil?  
M. Murkovic, S. Draxl, J. Winkler, W. Pfannhauser  
EURO FOOD CHEM IX, 24.9.-26.9.1997, Interlaken, Schweiz (Poster)

Bildung von 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridin (PhIP) einem Kanzerogen aus gebratenem Fleisch in Modellreaktionen  
S. Geiszler, M. Murkovic, W. Pfannhauser  
Österreichische Lebensmittelchemiker Tage, 12.9.-13.9.1997, Graz (Poster)

Oxidationsprodukte von a-Tocopherol in Speiseöl  
D. Wiltschko, M. Murkovic, W. Pfannhauser  
Österreichische Lebensmittelchemiker Tage, 12.9.-13.9.1997, Graz (Poster)

Tocopherolchinon als Abbauprodukt von Vitamin E in Milch  
C. Eixelsberger, M. Murkovic, W. Pfannhauser  
Österreichische Lebensmittelchemiker Tage, 12.9.-13.9.1997, Graz (Poster)

Vitamin B1 in österreichischem Getreide  
M. Murkovic, S. Draxl, W. Pfannhauser  
2. Seggauer Analysentage, 19.6.-20.6.1997, Seggau/Leibnitz (Poster)

Heterocyclic aromatic amines in fried poultry meat

M. Murkovic, M. Friedrich, W. Pfannhauser  
4<sup>th</sup> Symposium on Instrumental Analysis, 20.5-23.5.1997, Graz (Poster)

Bildung von heterozyklischen aromatischen Aminen in Modellsystemen  
M. Murkovic, S. Geiszler, K. Fröhlich, W. Pfannhauser  
GDCh-Hauptversammlung und 100-Jahrfeier der GÖCH, 7.9.-11.9.1997, Wien  
(Poster)

Chromium content in Austrian diets  
M. Wilplinger, W. Pfannhauser  
FAO-Meeting, 3./4.4.1997, Budapest (Poster)

Chromium supply in Austria  
Wilplinger M., Pfannhauser W.  
EURO FOOD CHEM IX, 24.9.-26.9.1997, Interlaken, Schweiz (Poster)

Determination of oxygenated compounds in spirits using a miniaturised plasma atomic emission detector  
D. Platzer, E. Kahr, G. Knapp, E. Leitner, W. Pfannhauser  
In Vino Analytica Scientia, 12.6.-14.6.1997, Bordeaux (Poster)

Determination of the sensorial properties of a convenient hen-broth  
B. Siegmund, I. Mayer, E. Leitner, W. Pfannhauser, P. Farkaš, J. Sádecká, M. Kováč  
5<sup>th</sup> Wartburg Aroma Symposium, 17.3.-20.3.1997, Eisenach, BRD (Poster)

The importance of a GC retention index database for flavour analysis demonstrated at the identification of aroma-active compounds of recooked dried hen meat  
Farkaš P., Pfannhauser W., Sádecká J., Pet'ka, M. Kováč, B. Siegmund, E. Leitner  
5<sup>th</sup> Wartburg Aroma Symposium, 17.3.-20.3.1997, Eisenach, BRD (Poster)

Qualität, Stabilität und Applikation von Anthocyaneen aus der Schwarzen Apfelbeere (*Aronia melanocarpa* Nero)  
H. Fuchs, A. Krämer-Schafhalter, S. Šilhar, M. Kováč, W. Pfannhauser  
100-Jahrfeier GÖCH, 26. GDCH-Hauptversammlung, 7.9.-11.9.1997, Wien (Poster)

Characterisation of anthocyanin colorants from Chokeberry (*Aronia melanocarpa*) by determination of quality parameters  
H. Fuchs, A. Krämer-Schafhalter, S. Šilhar, M. Kováč, W. Pfannhauser  
Euro Food Chem IX, 24.9.-26.9.1997, Interlaken, Schweiz (Poster)

Nahrungsmittel (Europäische Datenbank) in "Allergologie für die Praxis 5, Mönchengladbach 1996"  
R. van Eckert, W. Pfannhauser  
Hrsg. W. Jorde, Dustri-Verlag Dr. Karl Feistle, Deisenhofen bei München, 1. Aufl. 1997 (Poster)

Determination of proteins with ELISA-Methods: Doubtful quantitative results?  
R. van Eckert, W. Pfannhauser  
Euro Food Chem IX, 24.9.-26.9.1997, Interlaken, Schweiz (Poster)

Kapillarelektrophoretische Trennung von Weizenprolaminen  
R. van Eckert, H. Siegl, S. Zöchling, W. Pfannhauser

100-Jahrfeier GÖCH, 26. GDCH-Hauptversammlung, 7.9.-11.9.1997, Wien (Poster)

Antioxidantien und Gesundheit

W.Pfannhauser

Ernährung / nutrition 21, (11) 496 - 499 (1997)

Bestimmung des Fettgehaltes von Lebensmitteln durch Extraktion mit überkritischem Kohlendioxid

R.Melinz, S.Fister, W.Pfannhauser

Ernährung / nutrition 21, (12) 557 -561 (1997)

M. Wilplinger, W.Pfannhauser

Fragestellungen zur Magnesiumversorgung

Ernährung / nutrition 21, 321 – 23 (1997)

## 1998

Die elektronische Nase - eine neue Technik in der Lebensmittelsensorik

B. Siegmund, W. Pfannhauser

Ernährung/nutrition 22, 154-157 (1998)

Selengehalt in der Nahrung und dessen Zusammenhang zum Gehalt im Boden

M. Wilplinger, A. Sima, W.Pfannhauser

N. Lebensmittelchemie (1998) 52,93 – 95

M. Wilplinger, W. Pfannhauser

Chromium in Tea Leaves

Metal Ions in Biology and Medicin 5, 327 – 331 (1998)

M. Wilplinger, S. Zöchling, W. Pfannhauser

Chrom im Boden und in der Nahrung

VitaMinSpur (1998) 13, 117-120

M. Wilplinger, U. Schaller, W. Pfannhauser

Versorgung mit Nickel an verschiedenen Standorten in Österreich

Z.Lebensm. Unters. Forsch. (im Druck)

P.M. Abuja, M. Murkovic. W.Pfannhauser

Antioxidant and Prooxidant Activities of Elderberry (*Sambucus nigra*) Extract in Low-Density Lipoprotein Oxidation

J. Agric. Food Chem 1998, 46, 4091 – 96

A. Krämer-Schafhalter, H. Fuchs, W.Pfannhauser

B. Solid – Phase Extraction (SFE) – a comparison of 16 Materials for the Purification of Anthocyanins from *Aronia melanocarpa* var. Nero

J. Sci. Food Agric. 1998, 78, 435 - 440

M.Murkovic, D. Steinberger, W.Pfannhauser

Antioxidant spices reduce the formation of heterocyclic amines in fried meat

Z. Lebensm. Unters. Forsch. A 207, 477 – 480 (1998)

## 1999

M.Murkovic, H.-J. Weber, S. Geißler, K. Fröhlich, W.Pfannhauser  
Formation of the food associated carcinogen 2-amino-1-methyl[4,5-b]pyridine (PhIP)  
in model systems  
J.Food Chem 65, 233-237 (1999)

M. Wilplinger, S. Zöchling, W.Pfannhauser  
An Analysis of the Manganese Supply in Austria on the Basis of a Selected Diet  
Z. Lebensm. Unters. Forsch. A (1999) 208: 251 – 53

T. Wald, R van Eckert, A. Sima, W.Pfannhauser  
Untersuchung der Gliadinuntergruppen österreichischer Weizensorten  
Getreide Mehl und Brot 53, 1 (1999)

R. van Eckert, T. Wald, A. Sima, F. Repnegg, W.Pfannhauser  
Immunochemical Investigations of chromatographically separated Gliadin –  
Fractions  
Lebensmittelchem. 53, 29 (1999)

B.Siegmund, W. Pfannhauser  
Changes of the volatile fraction of cooked chicken meat during chill storage : results  
obtained by the electronic nose in comparison to GC – MS and GC olfactometry  
Z. Lebensm. Unters. Forsch A (1999) 208; 336 – 341

B.Siegmund, E. Leitner, W.Pfannhauser  
Development of a simple sample preparation technique for gas chromatographic-mass  
spectrometric determination of nicotine in edible nightshades (Solanaceae)  
J. Chromatography A 840, (1999) 249 – 260

B.Siegmund, E.Leitner, W.Pfannhauser  
Determination of the Nicotine Content of Various Edible Nightshades (Solanaceae)  
and Their Products and Estimation of the Associated Dietary Nicotine Intake  
J.Agric. Food Chem. 1999, 47, 3113 – 3120

S. Porta, W.Temmel, T. Gifford, J.Rand, D.Westmoreland, A.Sima, W.Pfannhauser,  
H. Bacher  
Human field experiments about the interrelationbsship of Magnesium, electrolyte and  
blood gas changes proportional to the intensity of accumulated workload – a  
diagnostic approach  
Magnesium Bulletin (1999) 3, 61 – 69

E.Leitner, W.Pfannhauser  
Identification of aroma active compounds in cardboard using solid phase  
microextraction (SME) coupled with GC-MS and GC-olfactometry  
In Frontiers of Flavour Science, 2000  
p- 74-78

**2000**

B. Siegmund, W. Pfannhauser

Chill storage of cooked chicken meat – changes in the volatile fraction observed by the electronic nose in comparison to GC-MS and GC-olfactometry

In *Frontiers of Flavour Science*, 2000

p. 148 – 152

G. Leitner, D. Westmoreland, M. Knapp, K. Spencer, J. Merback, V. Kruzik, M. Weger, W. Pfannhauser, S. Porta

Stress induced electrolyte and blood gas changes with and without a six days oral treatment with elderberry (*Sambucus Nigra L.*) concentrate

*Magnesium Bull.* 22,(3), 72-76 (2000)

M. Murkovic, W. Pfannhauser

Stability of pumpkin seed oil

*Eur. J. Lipid Sci. Technol.* 102, 607 – 611 (2000)

M. Murkovic, H. Toplak, U. Adam, W. Pfannhauser

Analysis of Anthocyanins in Plasma for Determination of their Bioavailability

*J. Food Comp. Anal.* 13, 291-96 (2000)

M. Murkovic, K. Gams, S. Draxl, W. Pfannhauser

Development of an Austrian Carotenoid Database

*J. Food Comp. Anal.* 13, 435-40 (2000)

A. Sima, M. Wilplinger, S. Zöchling, S. Heumann, U. Schaller, W. Pfannhauser

Trace Elements in Austrian Food

Trace Elements in Man and Animal Nutrition No 10

Ed. A.M. Roussel, R.A. Anderson, A.E. Favier

Kluwer Academic / Plenum Publishers, New York, Boston, Dordrecht, London, Moscow, 2000

p.239 – 241

W. Pfannhauser

Malnutrizione e micronutrienti : aspetti pratici in Austria

Malnutrizione – una sfida del terzo millennio per la società postindustriale – strategie di prevenzione e cura

Ed. L. Lucchin

Il Pensiero Scientifico Editore, Roma, 2000

p.255 – 263

Murkovic M, Toplak H, Adam U, Pfannhauser W :

Analysis of anthocyanins in serum for determination of their bioavailability *Journal of Food Composition and Analysis*, 13 (2000) 435-440 (2000)

Murkovic M, Adam U, Pfannhauser W :  
Analysis of anthocyanine glycosides in human serum Fresenius J Anal. Chem, Vol 366, pp 379-381 (2000)

Mülleder U, Murkovic M, Pfannhauser W :  
Analysis of metabolites of cyanidin glycosides Czech J. Food Sci., 18 (2000) 189 (2000)

Murkovic M, Gams K, Draxl S, Pfannhauser W :  
Development of an Austrian carotenoid database J. Food Comp. Analys. 13 (2000) 435-440 (2000)

## 2001

M. Murkovic, U. Mülleder, U. Adam, W. Pfannhauser  
„Detection of anthocyanins from elderberry juice in human urine  
J. Sci. Fd. Agric. 81: 934-37 (2001)

Simonova, W. Pfannhauser  
Einfluß der Lagerbedingungen auf die Bildung biogener Amine in Fleisch, Fisch und Gemüse  
Ernährung / nutrition 25: (6) 253-259 (2001)

Mülleder, U., Murkovic, M., Pfannhauser W. :  
Metabolism of cyanidin glycosides of elderberry. 2001 Pfannhauser, W., Fenwick, G.r., Khokhar, S. Biologically-active Phytochemicals in Food: Analysis, Metabolism, Bioavailability and Function. Cambridge, RSC, (2001)

B. Siegmund, D. E. Leyden, E. Zikulnig, E. Leitner, M. Murkovic, W. Pfannhauser, H. Reif  
The contribution of dietary nicotine and dietary cotinine to salivary cotinine levels as a nicotine biomarker  
Food Chemistry 74 (2001), 259 – 265; (2001)

## 2002

Bandoniene D, Murkovic M, Pfannhauser W, Venskutonis PR, Gruzdienė D :  
Detection and activity evaluation of radical scavenging compounds by using DPPH free radical and on-line HPLC-DPPH methods European Food Research and Technology, 214, 143-147 (2002)

Mülleder U, Murkovic M, Pfannhauser W :  
Urinary excretion of cyanidin glycosides J. Biochem. Biophys Methods, 53, 61-66, 2002 (2002)

K. Riediger, W. Pfannhauser  
Magnesium-, Calcium- und Kaliumversorgung bei österreichischen Grundwehrdienern  
Ernährung/Nutrition, Vol 26/nr. 10 2002, 401 – 407, (2002)

C. Bandonienė, M. Murkovic, W. Pfannhauser, R.R. Venskutonis, d. Gruzdienė  
Detection and activity evaluation of radical scavenging compounds by using DPPH free radical and on-line HPLC-DPPH methods  
Eur Food Res Technol (2002) 214:143 – 147, (2002)

## 2003

B.Siegmund, R. Weiss, W. Pfannhauser

Sensitive method for the determination of nitrated polycyclic aromatic hydrocarbons in the human diet

Anal Bioanal chem. (2003) 375: 175-181

O. Bejaoui-Kefi, S. Sabbah, M. Murkovic, M. Dachraoui, W. Pfannhauser

Red wines anthocyanins analyses by HPLC using different detection modes

Ernährung/Nutrition, Vol 27/Nr. 5 2003, 197 – 207, (2003)

S. Siegmund, K. Derler, W. Pfannhauser

Chemical and sensory effects of glass and laminated carton packages on fruit juice products – Still a controversial topic

Swiss Society of Food Science and Technology. Published by Elsevier Ltd., Lebensm.-Wiss. u.-Technol. 37 (2004) 481 – 488, (2004)

## 2004

P. Bejaoui Kefi, S. Ssbbah, M. Dachraoui and W. Pfannhauser

HPLC determination of free phenolic acids using electrochemical, UV and ESI-MS detection methods and their Application to Tunisian red wines

Ernährung/Nutrition Vol 28/Nr. 9 2004, 350 – 360, (2004)

T. Zierler, B. Siegmund, W. Pfannhauser

Determination of off-flavour compounds in apple juice caused by microorganisms using headspace solid phase microextraction-gas chromatography- mass spectrometry

Analytica Chimica Acta 520 (2004) 3-11

## **EXHIBIT B**

**DONALD VOET**

*University of Pennsylvania*

**JUDITH G. VOET**

*Swarthmore College*

**BIOCHEMISTRY**  
SECOND EDITION



**JOHN WILEY & SONS, INC.**

*New York Chichester Brisbane  
Toronto Singapore*

Acquisitions Editor: *Nedah Rose*  
Marketing Manager: *Catherine Faduska*  
Designer: *Madelyn Lesure*  
Manufacturing Manager: *Susan Stetzer*  
Photo Researcher: *Hilary Newman*  
Illustration Coordinator: *Edward Starr*

Illustrators: *J/B Woolsey Associates*

Production Management: *Pamela Kennedy Oborski and Suzanne Ingrao*

Cover and Part Opening Illustrations © *Irving Geis*

This book was set in 9.5/12 Times Roman by Progressive Information Technologies and printed and bound by Von Hoffman Press. The cover was printed by Lehigh Press Lithographers. Color separations by Lehigh Press Colortronics.

Recognizing the importance of preserving what has been written, it is a policy of John Wiley & Sons, Inc. to have books of enduring value published in the United States printed on acid-free paper, and we exert our best efforts to that end.

John Wiley & Sons, Inc., places great value on the environment and is actively involved in efforts to preserve it. Currently, paper of high enough quality to reproduce full-color art effectively contains a maximum of 10% recovered and recycled post-consumer fiber. Wherever possible, Wiley uses paper containing the maximum amount of recycled fibers. In addition, the paper in this book was manufactured by a mill whose forest management programs include sustained yield harvesting of its timberlands. Sustained yield harvesting principles ensure that the number of trees cut each year does not exceed the amount of new growth.



**TOTAL 10% RECYCLED PAPER**  
**ALL POST-CONSUMER WASTE**

Copyright © 1995, by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Sections 107 and 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

ISBN: 0-471-58651-X

Printed in the United States of America

10 9 8 7 6 5 4 3 2

*Cover Art:* Two paintings of horse heart cytochrome c by Irving Geis in which the protein is illuminated by its single iron atom. On the front cover the hydrophilic side chains are drawn in green, and on the back cover the hydrophobic side chains are drawn in orange. The paintings are based on an X-ray structure by Richard Dickerson.

## SOME COMMON BIOCHEMICAL ABBREVIATIONS<sup>a</sup>

A	adenine	ER	endoplasmic reticulum
aa	amino acid	FAD	flavin adenine dinucleotide, oxidized form
aaRS	amino-acyl tRNA synthetase	FADH	flavin adenine dinucleotide, radical form*
ACAT	acyl-CoA:cholesterol acyl transferase	FADH <sub>2</sub>	flavin adenine dinucleotide, reduced form†
ACh	acetylcholine	FBP	fructose-1,6-bisphosphate
ACP	acyl carrier protein	FBPase	fructose-1,6-biphosphatase
ADA	adenosine deaminase	Fd	ferredoxin
ADH	alcohol dehydrogenase	FH	familial hypercholesterolemia
ADP	adenosine diphosphate	fMet	N-formylmethionine
AIDS	acquired immunodeficiency syndrome	FMN	flavin mononucleotide‡
AMP	adenosine monophosphate	F1P	fructose-1-phosphate
AMPK	AMP-dependent protein kinase	F6P	fructose-6-phosphate
ALA	δ-aminolevulinic acid	G	guanine
ATCase	aspartate transcarbamoylase	GABA	γ-aminobutyric acid
ATP	adenosine triphosphate	Gal	galactose
BChl	bacteriochlorophyll	GalNAc	N-acetylgalactosamine
bp	base pair	GAP	glyceraldehyde-3-phosphate
BPG	D-2,3-bisphosphoglycerate	GAPDH	glyceraldehyde-3-phosphate dehydrogenase
BPheo	bacteriopheophytin	GC	gas chromatography
BPTI	bovine pancreatic trypsin inhibitor	GDP	guanosine diphosphate
C	cytosine	Glc	glucose
CaM	calmodulin	GMP	guanosine monophosphate
cAMP	cyclic AMP	G1P	glucose-1-phosphate
CAP	catabolite gene activating protein	G6P	glucose-6-phosphate
cAPK	cAMP-dependent protein kinase	GPI	glycosylphosphatidyl inositol
cDNA	complimentary DNA	GSH	glutathione
CDP	cytidine diphosphate	GSSG	glutathione disulfide
CDR	complimentarity determining region	GTP	guanosine triphosphate
CE	capillary electrophoresis	HA	hemagglutinin
Chl	chlorophyll	Hb	hemoglobin
CM	carboxymethyl	HDL	high density lipoprotein
CMP	cytidine monophosphate	HGPRT	hypoxanthine–guanine phosphoribosyl transferase
CoA or CoASH	coenzyme A	HIV	human immunodeficiency virus
CoQ	coenzyme Q (ubiquinone)	HMG-CoA	β-hydroxy-β-methylglutaryl-CoA
CTP	cytidine triphosphate	hnRNA	heterogeneous nuclear RNA
D	dalton	HPLC	high-performance liquid chromatography
d	deoxy	hsp	heat shock protein
dd	dideoxy	Hyl	5-hydroxylysine
DEAE	diethylaminoethyl	Hyp	4-hydroxyproline
DG	sn-1,2-diacylglycerol	IDL	intermediate density lipoprotein
DHAP	dihydroxyacetone phosphate	IF	initiation factor
DHF	dihydrofolate	IgG	immunoglobulin G
DHFR	dihydrofolate reductase	IHP	inositol hexaphosphate
DMF	N,N-dimethylformamide	IMP	inosine monophosphate
DMS	dimethyl sulfate	IP <sub>1</sub>	inositol-1-phosphate
DNP	2,4-dinitrophenol	IP <sub>3</sub>	inositol 1, 4, 5-triphosphate
DNA	deoxyribonucleic acid	IPTG	isopropylthiogalactoside
Dol	dolichol	IR	infrared
L-DOPA	L-3,4-dihydroxyphenylalanine	IS	insertion sequence
EF	elongation factor	ITP	inosine triphosphate
EGF	epidermal growth factor	K <sub>M</sub>	Michaelis constant
EPR	electron paramagnetic resonance	kb	kilo base pair

<sup>a</sup> The three-letter and one-letter abbreviations for the “standard” amino acid residues are given in Table 4-1.

---

kD	kilodaltons	PRPP	5-phosphoribosyl- $\alpha$ -pyrophosphate
KF	Klenow fragment	PS	photosystem
LCAT	lecithin:cholesterol acyl transferase	PSTV	potato spindle tuber virus
LDH	lactate dehydrogenase	Q	ubiquinone (CoQ)
LDL	low density lipoprotein	QH <sub>2</sub>	ubiquinol
Man	mannose	r	ribo
Mb	myoglobin	RER	rough endoplasmic reticulum
MHC	major histocompatibility complex	RF	release factor <i>or</i> replicative form
mRNA	messenger RNA	RFLP	restriction-fragment length polymorphism
MS	mass spectrometry	RK	HMG-CoA reductase kinase
NA	neuraminidase	RNA	ribonucleic acid
NAD <sup>+</sup>	nicotinamide adenine dinucleotide, oxidized form	RNAP	RNA polymerase
NADH	nicotinamide adenine dinucleotide, reduced form	R5P	ribose-5-phosphate
NADP <sup>+</sup>	nicotinamide adenine dinucleotide, phosphate, oxidized form	RPC	reverse phase chromatography
NADPH	nicotinamide adenine dinucleotide phosphate, reduced form	rRNA	ribosomal RNA
NAG	N-acetylglucosamine	RSV	Rous sarcoma virus
NAM	N-acetylmuramic acid	RT	reverse transcriptase
NANA	N-acetylneurameric (sialic) acid	RTK	receptor tyrosine kinase
NER	nucleotide excision repair	Ru1,5P	ribulose-1,5-bisphosphate
NMN	nicotinamide mononucleotide	Ru5P	ribulose-5-phosphate
NMR	nuclear magnetic resonance	S	Svedberg unit
NOESY	nuclear Overhauser effect spectroscopy	SAM	S-adenosylmethionine
P or p	phosphate	SCID	severe combined immunodeficiency disease
P <sub>i</sub>	orthophosphate ion	SDS	sodium dodecyl sulfate
PAGE	polyacrylamide gel electrophoresis	snRNA	small nuclear RNA
PBG	porphobilinogen	snRNP	small ribonuclear protein
PC	plastocyanin	S7P	sedoheptulose-7-phosphate
PCR	polymerase chain reaction	SRP	signal recognition particle
PE	phosphatidylethanolamine	T	thymine
PEP	phosphoenolpyruvate	TBP	TATA box-binding protein
PEPCK	PEP carboxykinase	TBSV	tomato bushy stunt virus
PFG	pulsed-field gel electrophoresis	TCA	tricarboxylic acid
PFK	phosphofructokinase	THF	tetrahydrofolate
PG	prostaglandin	TIM	triose phosphate isomerase
2PG	2-phosphoglycerate	TLC	thin layer chromatography
3PG	3-phosphoglycerate	TMV	tobacco mosaic virus
PDGF	platelet-derived growth factor	TPP	thiamine pyrophosphate
PGI	phosphoglucose isomerase	tRNA	transfer RNA
PGK	phosphoglycerate kinase	TS	thymidylate synthase
PGM	phosphoglycerate mutase	TTP	thymidine triphosphate
Pheo	pheophytin	U	uracil
PIP <sub>2</sub>	phosphatidylinositol-4,5-bisphosphate	UDP	uridine diphosphate
PK	pyruvate kinase	UDPG	UDP-glucose
PKU	phenylketonuria	UMP	uridine monophosphate
PLP	pyridoxal-5-phosphate	UTP	uridine triphosphate
PNP	purine nucleotide phosphorylase	UV	ultraviolet
Pol	DNA polymerase	<i>V</i> <sub>max</sub>	maximal velocity
PP <sub>i</sub>	pyrophosphate ion	VLDL	very low density lipoprotein
PrP	prion protein	XMP	xanthosine monophosphate
		XP	xeroderma pigmentosum
		Xu5P	xylulose-t-phosphate
		YAC	yeast artificial chromosome
		YADH	yeast alcohol dehydrogenase

---

## **EXHIBIT C**

**DONALD VOET**

*University of Pennsylvania*

**JUDITH G. VOET**

*Swarthmore College*

**BIOCHEMISTRY**  
SECOND EDITION



**JOHN WILEY & SONS, INC.**

*New York Chichester Brisbane  
Toronto Singapore*

Acquisitions Editor: *Nedah Rose*  
Marketing Manager: *Catherine Faduska*  
Designer: *Madelyn Lesure*  
Manufacturing Manager: *Susan Stetzer*  
Photo Researcher: *Hilary Newman*  
Illustration Coordinator: *Edward Starr*

Illustrators: *J/B Woolsey Associates*

Production Management: *Pamela Kennedy Oborski and Suzanne Ingrao*

Cover and Part Opening Illustrations © *Irving Geis*  
This book was set in 9.5/12 Times Roman by Progressive Information Technologies and printed and bound by Von Hoffman Press. The cover was printed by Lehigh Press Lithographers. Color separations by Lehigh Press Colortronics.

Recognizing the importance of preserving what has been written, it is a policy of John Wiley & Sons, Inc. to have books of enduring value published in the United States printed on acid-free paper, and we exert our best efforts to that end.

John Wiley & Sons, Inc., places great value on the environment and is actively involved in efforts to preserve it. Currently, paper of high enough quality to reproduce full-color art effectively contains a maximum of 10% recovered and recycled post-consumer fiber. Wherever possible, Wiley uses paper containing the maximum amount of recycled fibers. In addition, the paper in this book was manufactured by a mill whose forest management programs include sustained yield harvesting of its timberlands. Sustained yield harvesting principles ensure that the number of trees cut each year does not exceed the amount of new growth.



**TOTAL 10% RECYCLED PAPER**  
**ALL POST-CONSUMER WASTE**

Copyright © 1995, by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Sections 107 and 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

ISBN: 0-471-58651-X

Printed in the United States of America

10 9 8 7 6 5 4 3 2

*Cover Art:* Two paintings of horse heart cytochrome c by Irving Geis in which the protein is illuminated by its single iron atom. On the front cover the hydrophilic side chains are drawn in green, and on the back cover the hydrophobic side chains are drawn in orange. The paintings are based on an X-ray structure by Richard Dickerson.

complex with DNA, 1162  
 Estrogen response element (ERE), 1162  
 Estrogens, 703F, 1159, 1167, 1263T, 1269, 1272  
     and HDL levels, 324–325  
 ETF. *See* electron-transfer flavoprotein.  
 ETF:ubiquinone oxidoreductase, 669F  
 Ethanol, 53, 334F, 785  
     from alcoholic fermentation, 466  
     prochirality of, 66F  
 Ethanolamine, 281T, 713–714F  
 Ethanolamine kinase, 714F  
 Ethanolamine plasmalogen, 716F  
 Ethidium, 926  
 Ethidium ion, 871F–872F, 877F–878F  
 Ethylene, as a plant hormone, 1007  
 Ethylene glycol, 180F  
 $O^6$  Ethylguanine, 1046  
*N*-Ethylmaleimide, 120F  
 Ethylmethanesulfonate, 1053F  
 Ethylnitrosourea, 961F  
 Ethylthiofluoroacetate, 120F  
 Euchromatin, 1024F, 1149  
 Eukaryotes, 6–13  
     cellular architecture of, 6–11  
 Eukaryotic gene expression, 1123–1189  
 European corn borer, 908  
 Evans, M., 177  
*eve*. *See* even-skipped gene.  
 Eve protein, 1176  
*even-skipped* gene (*eve*), 1175  
 Evolution, by gene duplication, 131–132  
     by gene duplication, 209–211  
     by neutral drift, 125  
     chemical, 21–22, 123–132  
     convergent, 210, 394, 457  
     Darwinian, 125  
     divergent, 211, 457  
     lines of descent, 12F  
     organismal, 130–131  
     rate of, 129–130F  
     stages of, 19F, 20  
     structural, 208–211  
     through natural selection, 123–125  
 Excisionase, 1100  
 Excitatory synapses, 1296  
 Exclusion limit, 83  
 Exergonic processes, 47  
 Exiton transfer, 631–632F  
 Exit site. *See* E-site.  
 Exo conformation, 864–865F  
 Exocrine gland, 1262  
 Exocytosis, 8, 523F  
 Exoglycosylases, 259  
 Exonucleases, 883  
 Exons, 946–948, 951, 954–955, 1143F–1146  
     number of in proteins, 1146  
 Exopeptidases, 108  
 Exothermic processes, 43  
 Expressed sequences. *See* exons.  
 Expression vector, 906  
 Extensive quantities, 52  
 Extracellular-signal-regulated kinases (ERKs), 1285F–1286  
     in Ras signaling cascade, 1286  
 Extrinsic pathway, 1197F, 1205, 1206  
 Extrinsic proteins. *See* peripheral proteins.  
 Eyring, E., 348  
 F-Actin, 1239F–1242F, 1245, 1251  
     atomic model of, 1243–1244F  
     image reconstruction of, 1239F  
     model of S1 decoration, 1240  
 Fab, crystallized with reverse transcriptase, 1042  
     response to antigen binding, 1216–1218F  
 X-ray structure of hemagglutinin complex, 1217–1218F  
 X-ray structure of myohemerythrin segment complex, 1217–1218F  
 Fab fragment, 1211F–1212, 1215F  
     complexes with lysozyme, 1216–1217F  
 Fabry's disease, 720T–721F  
 Facilitated diffusion, 306, 514  
 Factor  $\bar{B}$ , 1230T, 1233  
 Factor  $\bar{D}$ , 1230T, 1233  
 Factor H, 1230T, 1233  
 Factor I (of complement system), 1230T, 1233  
 Factor I. *See* fibrinogen.  
 Factor II. *See* prothrombin.  
 Factor III. *See* thromboplastin.  
 Factor IV. *See*  $Ca^{2+}$ .  
 Factor V. *See* proaccelerin.  
 Factor VII. *See* proconvertin.  
 Factor VIII. *See* antihemophilic factor.  
 Factor IX. *See* Christmas factor.  
 Factor X. *See* Stuart factor.  
 Factor XI. *See* plasma thromboplastin antecedent.  
 Factor XII. *See* Hageman factor.  
 Factor XIII. *See* fibrin-stabilizing factor.  
 Facultative chromatin, 1149  
 FAD (flavin adenine dinucleotide, oxidized form), 400–401F, 731, 740, 787, 824F–825  
     in  $\beta$  oxidation, 668–670F  
     in dihydrolipoyl dehydrogenase, 543F, 544T  
     in glycerophosphate shuttle, 567F  
     in succinate dehydrogenase, 554–555F  
     production of ATP through, 556  
 FADH $^{\cdot}$  (flavin adenine dinucleotide, radical form), 401F  
 FADH $^{\cdot}_2$  (flavin adenine dinucleotide, reduced form), 401F, 787  
     ATP yield from, 568–569  
 FAD pyrophosphorylase, 824F–825  
 FAICAR. *See* 5-Formaminoimidazole-4-carboxamide ribotide.  
 Familial CJD, 1118  
 Familial hypercholesterolemia (FH), 324, 701–702F  
     and gene therapy, 908  
 Family tree, human, 1144F  
 Faraday constant ( $F$ ), 43T, 435, 583  
 Farber's lipogranulomatosis, 720T–721F  
 Farnesyl pyrophosphate, 694–697F  
 Farnesyl pyrophosphate synthase, 694  
 Farnesylated proteins, 314F, 692F–693, 700  
 Fasman, G., 202  
 Fast atom bombardment, 117  
 Fast-twitch muscle fibers, 469–470, 606  
 Fat, brown. *See* brown adipose tissue.  
 Fatal familial insomnia (FFH), 1118  
 Fat cells. *See* adipocytes.  
 Fats. *See* triacylglycerols.  
 Fatty acid biosynthesis, 560, 680–688  
     differences from  $\beta$  oxidation, 681F  
 Fatty acid metabolism,  
     regulation of, 688, 690–691  
     summary of, 787  
 Fatty acids, 278–279, 666, 787, 789–792  
     activation of, 667–668  
     degradation of, 666–678  
     desaturation of, 687–688  
     elongation of, 687–688  
     energetic yield on oxidation, 672  
     metabolic fates of, 791  
     odd-chain, 673–677  
     physical properties of, 279  
     transport into mitochondria, 668  
     unsaturated, 272–273, 672–673, 687–688  
 Fatty acid synthase, 421, 635–639, 691F  
     exons of, 1144–1145F  
     mechanism of, 684F–686  
     multifunctional enzyme, 683–685F  
 Fatty acyl-ACP, 681F  
 Fatty acylated proteins, 314  
 Fatty acyl-CoA, 668–669F, 681F, 790  
 Fatty acyl-CoA desaturases, 687–688F  
 Fatty streak lesions, 325  
 Fava bean, 622  
 Favism, 622  
 FBP. *See* fructose-1,6-bisphosphate.  
 FBPase. *See* Fructose-1,6-bisphosphatase.  
 FBPase-2. *See* fructose bisphosphatase-2.  
 FCCP. *See* Carbonylcyanide-*p*-trifluoromethoxyphenylhydrazone.  
 Fc fragment, 1211F–1212, 1215F  
 FDNB. *See* 1-fluoro-2,4-dinitrobenzene.  
 FdUMP. *See* 5-Fluorodeoxyuridine.  
 Feedback inhibition, 339  
 Feher, G., 634  
 Feigon, J., 1045  
 Felsenfeld, G., 1152  
 FeMo-cofactor, 778F–780  
 Fe protein, 776, 778–781  
     [4Fe–4S] cluster in, 778F  
     X-ray structure of, 778F–780  
 Fermentation, 5  
     alcoholic, 333, 444F–445, 466–469  
     homolactic, 444F–445, 464–466  
 Ferredoxin, 574F, 640F–641F, 645, 655F, 780F  
 Ferredoxin–NADP $^{\cdot}$  reductase, 640F–601, 645  
     X-ray structure of, 645–646F  
 Ferredoxin-thioredoxin reductase, 655F  
 Ferritin, 273F  
 Ferrochelatase, 754–755F  
 Ferryl oxidation state, 581F–582  
 Fetal hemoglobin. *See* HbF.  
 Feulgen reagent, 1124F  
 F factor, 838  
 F $^{\prime}$  factor, 840–841, 918  
 FFH. *See* fatal familial insomnia.  
 F $_1$ F $_0$ -ATPase. *See* proton-translocating ATPase.  
 FGAM. *See* formylglycinamide ribotide.  
 FGAM synthetase, 798F  
 FGAR. *See* formylglycinamide ribotide.  
 FH. *See* familial hypercholesterolemia.  
 Fibrin, 129

breakdown of, 1206  
 fibers of, 1198F–1200F  
 formation of, 1198–1201  
 Fibrinogen, 99, 129, 1197–1198T, 1206, 1207  
     activation of, 1198–1201  
     electron micrograph of, 1199F  
     structure of, 1198–1199F  
 Fibrinolysis, 1206  
 Fibrin-stabilizing factor (FSF), 1197–1198T, 1200–1201, 1207  
 Fibropetides, 1198–1200F  
     evolution of, 128–129F  
 Fibroblast, 8F  
 Fibroblast interferon, 1006  
 Fibroin, 155  
 Fibrous proteins. *See* proteins, fibrous.  
 Fick's first law of diffusion, 514  
 Fiers, W., 883  
 50S subunit. *See* ribosomal large subunit.  
 Figure-8 structure, 1054–1055F  
 Filter binding assay, 1275  
 Finch, J., 1127  
 Fingerprinting, 91, 119, 391, 962  
 Fink, G., 1065  
 First committed step, 414–415  
 First law of thermodynamics, 43–44, 627  
 First-order rate constants, determination of, 346F  
 First-order reactions, 346  
 Fischer, E., 65, 245, 253, 333  
 Fischer convention, 64–65, 253  
 Fischer projections, 64F  
 5S RNA, 930, 950F, 982T, 984–985F, 987F, 988–989T  
     genes encoding, 1193F–1140F  
     NMR structure of, 985F  
 5.8S RNA, 989T, 1138F  
 FK506, 200F–201, 1208  
 FK506 binding protein (FK506BP), 200  
 FK506BP. *See* FK506 binding protein.  
 Flagella, 4  
     bacterial, 1259–1260  
     eukaryotic, 1256  
     prokaryotic, 1234  
     rotary motion of in bacteria, 1259F–1260  
     structure of, 1260F  
 Flagellar filament, 1259F  
 Flagellar hook, 1259F  
 Flagellin, 10, 1001, 1259  
     H1, 1062–1064  
     H2, 1062–1064  
 FLAP. *See* 5-lipoxygenase-activating protein.  
 Flavin adenine dinucleotide, oxidized form. *See* FAD.  
     radical form. *See* FADH<sub>1</sub>.  
     reduced form. *See* FADH<sub>2</sub>.  
 Flavin coenzymes, 337T–338T  
     biosynthesis of, 825  
 Flavin mononucleotide. *See* FMN.  
 Flavins, 401, 746F–747  
 Flavodoxin, 77F  
 Flavokinase, 825F  
 Flavoprotein dehydrogenase, 567F  
 Flavoproteins, 401  
 Flagella, 10  
 Fleming, A., 269  
 Fletterick, R., 46  
 Flipases, 306  
 Flip-flops, 287F, 294, 306  
 Flows,  
     conjugate, 438  
     nonconjugate, 438  
 Flu. *See* influenza.  
 Fluid mosaic model, 297–299  
 Fluorescamine, 93, 94F  
 Fluorescence, 630F, 631  
 Fluorescence photobleaching recovery, 287–288F, 290  
 Fluoride, 421  
 Fluoroacetyl-CoA, 552F  
 Fluorochlorobromomethane, 63F  
 5-Fluorocytosine, 1066F–1067F  
 5-Fluorodeoxyuridine, 814  
 5-Fluorodeoxyuridylate (FdUMP), 813F, 815F, 828  
 1-Fluoro-2,4-dinitrobenzene (FDNB), 119F, 120F, 1214  
 Fluorophore, 288  
 5-Fluorouracil, 814  
 Flurbiprofen, 709F–710  
 Fluoroacetate, toxicity of, 552F  
 Fluorocitrate, inhibition of aconitase, 552F  
 Flux, 439, 443, 470  
     control by rate-determining step, 471  
     control by substrate cycling, 474–475  
     control of, 470–476  
     generation of, 470–471  
     variation of enzymatic rates with, 470–472  
 Flux-generating enzymes, 439–440  
 Flux-generating step, 470  
 FMDV. *See* foot-and-mouth disease virus.  
 fMet. *See* N-formylmethionine.  
 FMN (flavin mononucleotide), 573F–575F, 804–805, 825F  
     in Complex I, 573F, 575  
     in redox loop mechanism, 584F  
     oxidation states of, 575F  
 Foam cells, 324  
 Folate, 746F, 762F  
 Foldback structures, 1136–1137F  
 Folding accessory proteins, 198–202  
 Folic acid, 338F  
 Follicle-stimulating hormone (FSH), 1263T, 1271–1272F  
 Food energy content of, 663T  
 Foot-and-mouth disease, 1086  
 Foot-and-mouth disease virus (FMDV), 1087  
 Footprinting, 922  
     dimethyl sulfate, 895, 1057F  
     DNase I, 1057F  
 Force,  
     driving, 438  
     electromotive (emf), 435  
     proton-motive (pmf), 583  
     thermodynamic, 438  
 Foreign genes, expression in animals, 423–424  
 Forespore, 932  
 N-Formimino glutamate, 742F  
 Formaldehyde, 22  
 Formamidase, 744F  
 5-Formaminoimidazole-4-carboxamide  
     ribotide (FAICAR), 798F, 801  
 N<sup>5</sup>-Formimino-THF, 739, 740F, 762T–763F  
 N<sup>5</sup>-Formimino-THF cyclodeaminase, 763F  
 Formate, 763F  
 Formate dehydrogenase, 980  
 Formylglycinamide ribotide (FGAR), 798F–800F  
 Formylglycinamide ribotide (FGAM), 798F, 800F  
 N-Formylkynurenine, 744F  
 N-Formylmethionine (fMet), 67–68F, 991F  
     removal of, 1007  
 Formylmethionine-tRNA, 763F–764  
 N<sup>10</sup>-Formyl-THF, 712T–713F, 762T–763F, 798F–799, 992  
 Formyl-THF isomerase, 763F  
 N<sup>10</sup>Formyl-THF synthetase, 763F  
 45S RNA, 950F, 1138F  
 Fos protein, 1285F–1286  
     in Ras signaling cascade, [4Fe–4S] cluster, in aconitase, 551F  
 Fowler's solution, 547  
 Foxglove, purple, 526–527F  
 F<sub>0</sub> particles, 587–590  
 F<sub>1</sub> particles, 587–590  
     X-ray structure of, 588–590  
 F pili, 838F  
 Fractional saturation, 217  
 Fragile X syndrome, 1068–1069  
 Fragment 1 of prothrombin,  
     X-ray structure of, 1203F  
 Fragment reaction, 999  
 Frameshift mutations, 962  
 Frameshift suppressors, 981  
 Frank, H., 177  
 Franklin, B., 285  
 Franklin, R., 851  
 Free energy, 47–48  
     concentration dependence of, 51–52  
     of activation, 349–350  
     of formation, 49, 50T  
     of phosphate hydrolysis, 430T  
     partial molar, 48  
     work and, 48  
 Freeman, H., 644  
 Freeze-etch electron microscopy, 298–299F  
 Freeze-fracture electron microscopy, 298–299F, 646  
 Frictional coefficient, 89  
 Frictional ratio, aa 99  
     of proteins, 97T  
 Fructofuranose, 254F  
 β-Fructofuranosidase, 351  
     *See also* α-D-glucosidase.  
 Fructokinase, 476F–477  
 Fructose, 253F, 450F  
     furanose form of, 254F  
     linear form of, 254F  
     metabolism of, 476F–477  
 Fructose bisphosphatase-2 (FBPase-2), 506–507, 789  
     regulation of, 605T–606F  
     inhibition by fructose-2,6-bisphosphatase (F2,6BP), 506F–507  
 Fructose-1,6-bisphosphatase (FBPase), 341–342, 475, 491, 650F, 652, 654–655F, 786, 789  
     in gluconeogenesis, 603–605F  
     light activation of, 654–655F  
     regulation of, 605T–606F

globular heads of, 1236–1238F  
heavy chain of, 1236T–1239  
nonmuscle, 1250–1253  
regulatory light chain (RLC) of, 1236T–1239

Myosin–actin complex, atomic model of, 1244–1246

Myosin light chain kinase (MLCK), 501F–502, 1249–1250F, 1252  
in platelet contraction, 1252  
pseudosubstrate peptide of, 502

Myosin light chain phosphatase, 1249–1250F

Myosin light chains, 1236T–1239  
function of, 1243, 1249

Myosin I, 1253F

Myosin subfragment-1 (S1), 1238F–1241, 1245F–1248  
model decorating F-actin, 1240F  
X-ray structure of, 1238F–1239

Myosin subfragment-2 (S2), 1238F–1239

Myosin II, 1253F

Myotonic dystrophy (DM), 1069

Myristic acid, 278T  
in fatty acylated proteins, 314

Myosin subfragment-1, model decorating F-actin, 1240  
X-ray structure of, 1238F–1239

N regions, in heavy chain genes, 1221–1222

n Protein. *See* priB protein.

n' Protein. *See* priA protein.

n'' Protein. *See* priC protein.

NA. *See* neuraminidase.

(Na<sup>+</sup>–Ca<sup>2+</sup>) antiport, cardiac, 527

Na<sup>+</sup>channels, 1293–1295

Na<sup>+</sup>–glucose symport, 531–532F  
mechanism of, 501F

(Na<sup>+</sup>–K<sup>+</sup>). *See* (Na<sup>+</sup>–K<sup>+</sup>)–ATPase.

(Na<sup>+</sup>–K<sup>+</sup>)–ATPase, 524–527, 789, 1292  
conformational states of, 525–526F  
function of, 525  
inhibition by cardiac glycosides, 526–527  
mechanism of, 525–526F

(Na<sup>+</sup>–K<sup>+</sup>) pump. *See* (Na<sup>+</sup>–K<sup>+</sup>)–ATPase.

NAD<sup>+</sup> (nicotinamide adenine dinucleotide, oxidized form), 171, 172F, 334F, 785–787, 790, 792, 824F  
in dihydroliopoyl dehydrogenase reaction, 543F–545  
in DNA ligase reaction, 1029–1030F  
mitochondrial transport of, 566–568  
production of ATP through, 556  
regeneration by fermentation, 444F–445, 464–470

NAD<sup>+</sup> kinase, 824F–825

NAD<sup>+</sup> pyrophosphorylase, 824F–825

NAD<sup>+</sup> synthetase, 824F–825

NADH (nicotinamide adenine dinucleotide, reduced form), 334F, 785–787  
ATP yield, 568–569  
generation by glycolysis, 445, 457–459  
mitochondrial transport of, 603–604F

NADH–coenzyme Q reductase. *See* Complex I.

NADH–cytochrome b<sub>5</sub> reductase, 688F

NADH peroxidase, 406

NADP<sup>+</sup> (nicotinamide adenine dinucleotide phosphate, oxidized form), 334F, 786F–787, 824F  
in photosynthesis, 628

NADPH (nicotinamide adenine dinucleotide phosphate, reduced form), 334F, 414F, 599, 786F–787  
as cellular reducing currency, 617  
physiological distinction from NADH, 617  
production by pentose phosphate pathway, 618F–619, 622

NAG. *See* N-acetylglucosamine.

NAM. *See* N-acetylmuramic acid.

Namba, K., 1260

NANA. *See* N-acetylneurameric acid.

nanos gene, 1174F–1175

Nanos protein, 1174F–1175

Napoleon Bonaparte, arsenic poisoning of, 547

Naproxen, 709F

Nathans, D., 884

N-CAM. *See* Neural cell–adhesion molecule.

Nearest-neighbor analysis, 913

Negative cooperativity, 218

Negative regulation, 934, 940

N-end rule, 1014

NER. *See* nucleotide excision repair.

Nernst equation, 434–435, 437

Nernst, W., 435

Nernst–Planck equation, 514

Nerve gases, 390–391, 1299

Nerve growth factor (NGF) receptor, 1281F

Nervonic acid, 278T

Nervous system, 1207

Neuberg, C., 445

Neural cell–adhesion molecule (N-CAM), 1225F

Neuraminidase (NA), 312, 1107F–1108T, 1112F–1113  
antigenic variation of, 1112F–1113  
carbohydrates of, 1112F–1113  
X-ray structure of, 1112F–1113

Neurohypophysis, 1263T, 1271F, 1274

Neuromuscular junction, 1248

Neuron, 11F

Neuropeptides, 1301

Neurotoxins, 1293–1295

Neurotransmission, 1291–1301

Neurotransmitters, 390–391, 1291  
amino acids as, 1300–1301  
inhibitory, 1300  
polypeptides as, 1301

Neutral drift, 125

Neutral fats. *See* triacylglycerols.

Neutron diffraction, 987

Neutrophils, 1291

Newman projection, 66F

Newsholme, E., 475, 688

Nexin, 1256F

NF-E1 gene, 1188

NF-E1. *See* GATA-1.

NF-E2, 1158

NF-E3, 1158

NF-E4, 1158

Niacin. *See* nicotinic acid.

Niacinamide. *See* nicotinamide.

Nicholson, G., 297

Nick translation, 1027F, 1031

Nicking–closing enzyme. *See* type I topoisomerase.

Nicotinamide, 334, 337F–338T, 824F, 1004, 1280F

Nicotinamide adenine dinucleotide, oxidized form. *See* NAD<sup>+</sup>

Nicotinamide adenine dinucleotide, reduced form. *See* NADH

Nicotinamide adenine dinucleotide phosphate, oxidized form. *See* NADP<sup>+</sup>

Nicotinamide adenine dinucleotide phosphate, reduced form. *See* NADPH.

Nicotinamide coenzymes, 337–338  
biosynthesis of, 762, 764F–765  
*See also* NAD<sup>+</sup>, NADH, NADP<sup>+</sup>, and NADPH.

Nicotinamide mononucleotide (NMN), 824F–825

Nicotinamide phosphoribosyl transferase, 824F–825

Nicotinate, 824F

Nicotinate adenine dinucleotide, 824F–825

Nicotinate mononucleotide, 824F

Nicotinate phosphoribosyl transferase, 824F–825

Nicotine, 1296F

Nicotinic acid, 337F

Nicotinic receptors, 1296, 1301

NIDDM. *See* non-insulin-dependent diabetes mellitus.

Niedergerke, R., 1244

Niemann–Pick disease, 720T–721F

Nierhaus, K., 987

Nigericin, 598

NIH shift, 747–749F

9 + 2 assembly, 1256F

Ninhydrin reaction, 81–82F

Nirenberg, M., 963–964, 966

Nitric oxide (NO).  
as an intercellular messenger, 1290–1291  
binding to hemoglobin, 217, 227, 233

Nitrites, 598, 961  
reaction with cytosine, 1049

Nitrocellulose, 85, 94, 872–873, 903, 932, 965, 1275

Nitrogenase, 776, 778–781  
Fe protein of, 776, 778F–781  
inactivation by O<sub>2</sub>, 780

MoFe protein of, 778F–780  
*See also* MoFe protein.

Nitrogen fixation, 4, 776, 778–781  
ATP requirement for, 780–781  
electron flow in, 780F

Nitrogen mustard, 961F

Nitroglycerin, vasodilating effects of, 1290F

3-Nitro-2-S-hydroxypropionate, 555F

p-Nitrophenolate, 389F–390F

p-Nitrophenylacetate, 378F  
hydrolysis by chymotrypsin, 389F–390F

p-Nitrophenyldiazonium, 1214F

p-Nitrophenylguanidinobenzoate, 397F

Nitrosamines, 961

Nitrosoheme, 1291

Nitrous acid, 961

N-linked oligosaccharides, 271F–272, 609–615  
core of, 271–272  
cotranslational addition to proteins, 610–612  
glycoforms of, 272

## **EXHIBIT D**

**DONALD VOET**

*University of Pennsylvania*

**JUDITH G. VOET**

*Swarthmore College*

# BIOCHEMISTRY

SECOND EDITION



JOHN WILEY & SONS, INC.

*New York Chichester Brisbane  
Toronto Singapore*

Acquisitions Editor: *Nedah Rose*  
Marketing Manager: *Catherine Faduska*  
Designer: *Madelyn Lesure*  
Manufacturing Manager: *Susan Stetzer*  
Photo Researcher: *Hilary Newman*  
Illustration Coordinator: *Edward Starr*

Illustrators: *J/B Woolsey Associates*

Production Management: *Pamela Kennedy Oborski and Suzanne Ingrao*

Cover and Part Opening Illustrations © *Irving Geis*

This book was set in 9.5/12 Times Roman by Progressive Information Technologies and printed and bound by Von Hoffman Press. The cover was printed by Lehigh Press Lithographers. Color separations by Lehigh Press Colortronics.

*Cover Art:* Two paintings of horse heart cytochrome *c* by Irving Geis in which the protein is illuminated by its single iron atom. On the front cover the hydrophilic side chains are drawn in green, and on the back cover the hydrophobic side chains are drawn in orange. The paintings are based on an X-ray structure by Richard Dickerson.

Recognizing the importance of preserving what has been written, it is a policy of John Wiley & Sons, Inc. to have books of enduring value published in the United States printed on acid-free paper, and we exert our best efforts to that end.

John Wiley & Sons, Inc., places great value on the environment and is actively involved in efforts to preserve it. Currently, paper of high enough quality to reproduce full-color art effectively contains a maximum of 10% recovered and recycled post-consumer fiber. Wherever possible, Wiley uses paper containing the maximum amount of recycled fibers. In addition, the paper in this book was manufactured by a mill whose forest management programs include sustained yield harvesting of its timberlands. Sustained yield harvesting principles ensure that the number of trees cut each year does not exceed the amount of new growth.



**TOTAL 10% RECYCLED PAPER**  
**ALL POST-CONSUMER WASTE**

Copyright © 1995, by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Sections 107 and 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

ISBN: 0-471-58651-X

Printed in the United States of America

10 9 8 7 6 5 4 3 2

$O_2$  consumes twice as many moles of NADH as of  $O_2$ , the P/O ratio for NADH reoxidation at Region 2 is  $90 \mu\text{mol of ADP}/(2 \times 15 \mu\text{mol of } O_2) = 3$ ; that is, *3 mol of ADP are phosphorylated per mole of NADH oxidized*.

(b) The experiment is continued by inhibiting electron transfer from NADH by rotenone and adding an additional  $90 \mu\text{mol of ADP}$  (Fig. 20-12; Region 4), this time together with an excess of the FAD-linked substrate succinate. Oxygen consumption again continues until all the ADP is phosphorylated, and the system again returns to the resting state (Fig. 20-12; Region 5). Calculation of the P/O ratio for  $\text{FADH}_2$  oxidation yields the value 2; that is, *2 mol of ADP are phosphorylated per mole of  $\text{FADH}_2$  oxidized*.

(c) In the same manner, *the oxidation of ascorbate/TMPD yields a P/O ratio of 1* (Fig. 20-12; Regions 6 and 7).

These conclusions agree with the inhibitor studies indicating that there are three entry points for electrons into the electron-transport chain and with the standard reduction potential measurements exhibiting three potential jumps, each sufficient to provide the free energy for ATP synthesis (Fig. 20-8).

#### The P/O Ratios May Be Subject to Revision


Measurements of P/O ratios are subject to systematic experimental errors for which it is difficult to correct, such as inaccuracies in the measurement of the oxygen concentration, the presence of AMP, and proton leakage from mitochondria. Thus, the widely accepted P/O values of 3, 2, and 1 associated with NADH-,  $\text{FADH}_2$ -, and ascorbate/TMPD-linked oxidation may well be in error. Indeed, measurements by Peter Hinkle have yielded values close to 2.5, 1.5, and 1 for these quantities (we shall see in Section 20-3 that P/O ratios need not have integer values because the number of protons pumped out of the mitochondrion by any component of the electron transport chain may not be an integer multiple of the number of protons required to

synthesize ATP from  $\text{ADP} + \text{P}_i$ ). If these values are correct, then the number of ATPs that are synthesized per molecule of glucose oxidized is  $2.5 \text{ ATP}/\text{NADH} \times 10 \text{ NADH}/\text{glucose} + 1.5 \text{ ATP}/\text{FADH}_2 \times 2 \text{ FADH}_2/\text{glucose} + 2 \text{ ATP}/\text{glucose}$  from the citric acid cycle + 2 ATP/glucose from glycolysis = 32 ATP/glucose rather than the conventional value of 38 ATP/glucose implied by P/O ratios of 3, 2, and 1. However, since there is significant disagreement as to the validity of the revised P/O ratios, we shall, for the sake of consistency, use the more established values of 3, 2, and 1 throughout this textbook. You should nevertheless keep in mind that these values are disputed.

How the free energy of electron transport is actually coupled to ATP synthesis, a subject of active research, is discussed in Section 20-3. We first examine the structures of the four respiratory complexes in order to understand how they are related to the function of the electron-transport chain. Keep in mind, however, that as in most areas of biochemistry, this field is under intense investigation and much of the information we need for a complete understanding of these relationships has yet to be uncovered.

#### C. Components of the Electron-Transport Chain

Many of the proteins embedded in the inner mitochondrial membrane are organized into the four respiratory complexes of the electron-transport chain. Each complex consists of several protein components that are associated with a variety of redox-active prosthetic groups with successively increasing reduction potentials (Table 20-1). The complexes are all laterally mobile within the inner mitochondrial membrane; they do not appear to form any stable higher structures. Indeed, they are not present in equimolar ratios. In the following paragraphs, we examine their structures and the agents that transfer electrons between them. Their relationships are summarized in Fig. 20-13.



**FIGURE 20-13.** A diagram of the mitochondrial electron-transport chain indicating the pathway of electron transfer (black) and proton pumping (red). Electrons are transferred between Complexes I and III by the membrane-soluble CoQ


and between Complexes III and IV by the peripheral membrane protein cytochrome *c*. Complex II (not shown) transfers electrons from succinate to CoQ.

### 1. Complex I (NADH–Coenzyme Q Reductase)


Complex I passes electrons from NADH to CoQ. This probably largest protein component of the inner mitochondrial membrane (850 kD) contains one molecule of **flavin mononucleotide (FMN; a redox-active prosthetic group that differs from FAD only by the absence of the AMP group)** and six to seven **iron–sulfur clusters** that participate in the electron-transport process (Table 20-1).

#### Iron–Sulfur Clusters Are Redox Active

Three types of iron–sulfur clusters are known to occur as prosthetic groups of **iron–sulfur proteins (nonheme iron proteins)**:



The two most common types, designated **[2Fe–2S]** and **[4Fe–4S]** clusters, consist of equal numbers of iron and sulfide ions and are both coordinated to four protein Cys sulfhydryl groups. One means of identifying these clusters



**FIGURE 20-14.** The X-ray structure of ferredoxin from *Peptococcus aerogenes*, a monomeric 54-residue protein that contains two [4Fe–4S] clusters. The C<sub>β</sub> atoms of the four Cys residues liganding each [4Fe–4S] cluster are green, the Fe atoms are brown, and the S atoms are yellow. [Based on an X-ray structure by Elinor Adman, Larry Sieker, and Lyle Jensen, University of Washington.]

utilizes the fact that their sulfide ions are acid labile: They are released as H<sub>2</sub>S near pH 1. The **[Fe–S]** cluster, which has been found only in bacteria, consists of a single Fe atom liganded to four Cys residues. Note that the Fe atoms in all three types of clusters are each coordinated by four S atoms, which are more or less tetrahedrally disposed around the Fe. (A **[3Fe–4S]** cluster, which has been found in only one bacterial species, resembles a [4Fe–4S] cluster that lacks an Fe atom.) *The oxidized and reduced states of all iron–sulfur clusters differ by one formal charge regardless of their number of Fe atoms.* This is because the Fe atoms in each cluster form a conjugated system and thus can have oxidation states between the +2 and +3 values possible for individual Fe atoms. For example, each of the two [4Fe–4S] clusters in the protein **ferredoxin** (Fig. 20-14) contains one Fe(II) and three Fe(III)'s in its oxidized form and two Fe(II)'s and two Fe(III)'s in its reduced form. Iron–sulfur proteins also occur in the photosynthetic electron-transport chains of plants and bacteria (Section 22-2); indeed, photosynthetic electron-transport chains are thought to be the evolutionary precursors of oxidative electron-transport chains (Section 14C).




FIGURE 20-15. The oxidation states of (a) FMN and (b) CoQ. Both coenzymes form stable semiquinone free radical states.

### The Coenzymes of Complex I

FMN and CoQ, the coenzymes of Complex I, can each adopt three oxidation states (Fig. 20-15). Although NADH can only participate in a two-electron transfer, both FMN and CoQ are capable of accepting and donating either one or two electrons because their semiquinone forms are stable. In contrast, the cytochromes of Complex III (see below), to which reduced CoQ passes its electrons, are only capable of one-electron reductions. *FMN and CoQ therefore provide an electron conduit between the two-electron donor NADH and the one-electron acceptors, the cytochromes.*

CoQ's hydrophobic tail makes it soluble in the inner mitochondrial membrane's lipid bilayer. In mammals, this tail consists of 10 C<sub>5</sub> isoprenoid units and hence the coen-

zyme is designated Q<sub>10</sub>. In other organisms, CoQ may have only 6 (Q<sub>6</sub>) or 8 (Q<sub>8</sub>) isoprenoid units.

### 2. Complex II (Succinate–Coenzyme Q Reductase)

*Complex II, which contains the dimeric citric acid cycle enzyme succinate dehydrogenase (Section 19-3F) and three other small hydrophobic subunits, passes electrons from succinate to CoQ.* It does so with the participation of a covalently bound FAD, one [4Fe–4S] cluster, two [2Fe–2S] clusters, and one cytochrome b<sub>560</sub> (Table 20-1). We discuss the structures of the cytochromes in connection with that of Complex III below. [One of Complex II's iron–sulfur clusters has a standard reduction potential that is too negative (−0.245 V) to accept electrons from succinate; its function is unknown.]

## **EXHIBIT E**

# BIOCHEMISTRY

THIRD EDITION



LUBERT STRYER

STANFORD UNIVERSITY



W. H. FREEMAN AND COMPANY / NEW YORK

Library of Congress Cataloging-in-Publication Data

Stryer, Lubert.

Biochemistry.

Includes index.

1. Biochemistry. I. Title.

QP514.2.S66 1988 574.19'2 87-36486

ISBN 0-7167-1843-X

ISBN 0-7167-1920-7 (international student ed.)

Copyright © 1975, 1981, 1988 by Lubert Stryer

No part of this book may be reproduced by any mechanical, photographic, or electronic process, or in the form of a phonographic recording, nor may it be stored in a retrieval system, transmitted, or otherwise copied for public or private use, without written permission from the publisher.

Printed in the United States of America

2 3 4 5 6 7 8 9 0 RRD 6 5 4 3 2 1 0 8 9 8

## COMMON ABBREVIATIONS IN BIOCHEMISTRY

A	adenine	Hyp	hydroxyproline
ACP	acyl carrier protein	IgG	immunoglobulin G
ADP	adenosine diphosphate	Ile	isoleucine
Ala	alanine	IP <sub>3</sub>	inositol trisphosphate
AMP	adenosine monophosphate	ITP	inosine triphosphate
cAMP	cyclic AMP	LDL	low-density lipoprotein
cGMP	cyclic GMP	Leu	leucine
Arg	arginine	Lys	lysine
Asn	asparagine	Met	methionine
Asp	aspartate	NAD <sup>+</sup>	nicotinamide adenine dinucleotide (oxidized form)
ATP	adenosine triphosphate	NADH	nicotinamide adenine dinucleotide (reduced form)
ATPase	adenosine triphosphatase	NADP <sup>+</sup>	nicotinamide adenine dinucleotide phosphate (oxidized form)
C	cytosine	NADPH	nicotinamide adenine dinucleotide phosphate (reduced form)
CDP	cytidine diphosphate	PFK	phosphofructokinase
CMP	cytidine monophosphate	Phe	phenylalanine
CTP	cytidine triphosphate	P <sub>i</sub>	inorganic orthophosphate
CoA	coenzyme A	PLP	pyridoxal phosphate
CoQ	coenzyme Q (ubiquinone)	PP <sub>i</sub>	inorganic pyrophosphate
cyclic AMP	adenosine 3',5'-cyclic monophosphate	Pro	proline
cyclic GMP	guanosine 3',5'-cyclic monophosphate	PRPP	phosphoribosylpyrophosphate
Cys	cysteine	Q	ubiquinone (or plastoquinone)
cyt	cytochrome	QH <sub>2</sub>	ubiquinol (or plastoquinol)
d	2'-deoxyribo	RNA	ribonucleic acid
DNA	deoxyribonucleic acid	mRNA	messenger RNA
cDNA	complementary DNA	rRNA	ribosomal RNA
DNase	deoxyribonuclease	scRNA	small cytoplasmic RNA
EcoRI	EcoRI restriction endonuclease	snRNA	small nuclear RNA
FAD	flavin adenine dinucleotide (oxidized form)	tRNA	transfer RNA
FADH <sub>2</sub>	flavin adenine dinucleotide (reduced form)	RNase	ribonuclease
fMET	formylmethionine	Rubisco	ribulose 1,5-bisphosphate carboxylase
FMN	flavin mononucleotide (oxidized form)	Ser	serine
FMNH <sub>2</sub>	flavin mononucleotide (reduced form)	T	thymine
G	guanine	Thr	threonine
Gln	glutamine	TPP	thiamine pyrophosphate
Glu	glutamate	Trp	tryptophan
Gly	glycine	TTP	thymidine triphosphate
GDP	guanosine diphosphate	Tyr	tyrosine
GMP	guanosine monophosphate	U	uracil
GSH	reduced glutathione	UDP	uridine diphosphate
GSSG	oxidized glutathione	UDP-galactose	uridine diphosphate galactose
GTP	guanosine triphosphate	UDP-glucose	uridine diphosphate glucose
GTPase	guanosine triphosphatase	UMP	uridine monophosphate
Hb	hemoglobin	UTP	uridine triphosphate
HDL	high-density lipoprotein	Val	valine
HPRT	hypoxanthine-guanine phosphoribosyl transferase	VLDL	very low-density lipoprotein
His	histidine		

## **EXHIBIT F**

**DONALD VOET**

*University of Pennsylvania*

**JUDITH G. VOET**

*Swarthmore College*

**BIOCHEMISTRY**  
SECOND EDITION



**JOHN WILEY & SONS, INC.**

*New York Chichester Brisbane  
Toronto Singapore*

Acquisitions Editor: *Nedah Rose*  
Marketing Manager: *Catherine Faduska*  
Designer: *Madelyn Lesure*  
Manufacturing Manager: *Susan Stetzer*  
Photo Researcher: *Hilary Newman*  
Illustration Coordinator: *Edward Starr*

Illustrators: *J/B Woolsey Associates*

Production Management: *Pamela Kennedy Oborski and Suzanne Ingrao*

Cover and Part Opening Illustrations © *Irving Geis*

This book was set in 9.5/12 Times Roman by Progressive Information Technologies and printed and bound by Von Hoffman Press. The cover was printed by Lehigh Press Lithographers. Color separations by Lehigh Press Colortronics.

Recognizing the importance of preserving what has been written, it is a policy of John Wiley & Sons, Inc. to have books of enduring value published in the United States printed on acid-free paper, and we exert our best efforts to that end.

John Wiley & Sons, Inc., places great value on the environment and is actively involved in efforts to preserve it. Currently, paper of high enough quality to reproduce full-color art effectively contains a maximum of 10% recovered and recycled post-consumer fiber. Wherever possible, Wiley uses paper containing the maximum amount of recycled fibers. In addition, the paper in this book was manufactured by a mill whose forest management programs include sustained yield harvesting of its timberlands. Sustained yield harvesting principles ensure that the number of trees cut each year does not exceed the amount of new growth.



**TOTAL 10% RECYCLED PAPER**  
**ALL POST-CONSUMER WASTE**

Copyright © 1995, by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.


Reproduction or translation of any part of this work beyond that permitted by Sections 107 and 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

ISBN: 0-471-58651-X

Printed in the United States of America

10 9 8 7 6 5 4 3 2

*Cover Art:* Two paintings of horse heart cytochrome c by Irving Geis in which the protein is illuminated by its single iron atom. On the front cover the hydrophilic side chains are drawn in green, and on the back cover the hydrophobic side chains are drawn in orange. The paintings are based on an X-ray structure by Richard Dickerson.



## 25

# *Energy Metabolism: Integration and Organ Specialization*

1. Major Pathways and Strategies of Energy Metabolism: A Summary
2. Organ Specialization
  - A. Brain
  - B. Muscle
  - C. Adipose Tissue
  - D. Liver
3. Metabolic Adaptation
  - A. Starvation
  - B. Diabetes Mellitus

At this point in our narrative we have studied all of the major pathways of energy metabolism. Consequently, we are now in a position to consider how organisms, mammals in particular, orchestrate the metabolic symphony to meet their energy needs. This chapter therefore begins with a recapitulation of the major metabolic pathways and their control systems, then considers how these processes are apportioned among the various organs of the body, and ends with a discussion of how the body deals with the metabolic challenge of starvation and how it responds to the loss of control resulting from diabetes mellitus.

## **1. MAJOR PATHWAYS AND STRATEGIES OF ENERGY METABOLISM: A SUMMARY**

Figure 25-1 indicates the interrelationships among the major pathways involved in energy metabolism. Let us review these pathways and their control mechanisms.

### **1. Glycolysis (Chapter 16)**

The metabolic degradation of glucose begins with its conversion to two molecules of pyruvate with the net generation of two molecules each of ATP and NADH. Under anaerobic conditions, pyruvate is converted to lactate (or, in yeast, to ethanol) so as to recycle the NADH. Under aerobic conditions, however, when glycolysis serves to prepare glucose for further oxidation, the NAD<sup>+</sup> is regenerated through oxidative phosphorylation (see below). The flow of metabolites through the glycolytic pathway is largely controlled by the activity of phosphofructokinase (PFK). This enzyme is activated by AMP and ADP, whose concentrations rise as the need for energy metabolism increases, and is inhibited by ATP and citrate, whose concentrations increase when the demand for energy metabolism has slackened. PFK is also activated by fructose-2,6-bisphosphate, whose concentration is regulated by the levels of glucagon, epinephrine, and norepinephrine through the intermediacy




FIGURE 25-1. The major energy metabolism pathways.

of cAMP (Section 17-3F). Liver and heart muscle F2,6P<sub>2</sub> levels are regulated oppositely: A [cAMP] increase causes an [F2,6P<sub>2</sub>] decrease in liver and an [F2,6P<sub>2</sub>] increase in heart muscle.

## 2. Gluconeogenesis (Section 21-1)

Mammals can synthesize glucose from a variety of precursors, including pyruvate, lactate, glycerol, and glucogenic amino acids, through pathways that occur mainly in liver and kidney. Many of these precursors are converted to oxaloacetate which, in turn, is converted to

phosphoenolpyruvate and then, through a series of reactions that largely reverse the path of glycolysis, to glucose. The irreversible steps of glycolysis, those catalyzed by PFK and hexokinase, are bypassed in gluconeogenesis by hydrolytic reactions catalyzed, respectively, by fructose-1,6-bisphosphatase (FBPase) and glucose-6-phosphatase. FBPase and PFK may both be at least partially active simultaneously, creating a substrate cycle. This cycle, and the reciprocal regulation of PFK and FBPase, are important in regulating both the rate of glu-

direction of flux through glycolysis and gluconeogenesis (Sections 16-3 and 21-1B).

### 3. Glycogen degradation and synthesis (Chapter 17)

Glycogen, the storage form of glucose in animals, occurs mostly in liver and muscle. Its conversion to glucose-6-phosphate (G6P) for entry into glycolysis is catalyzed, in part, by glycogen phosphorylase, whereas the opposing synthetic pathway is mediated by glycogen synthase. These enzymes are reciprocally regulated through phosphorylation/dephosphorylation reactions as catalyzed by amplifying cascades that respond to the levels of the hormones glucagon and epinephrine through the intermediacy of cAMP.

### 4. Fatty acid degradation and synthesis (Sections 23-1 through 23-5)

Fatty acids are broken down in increments of  $C_2$  units through  $\beta$  oxidation to form acetyl-CoA. They are synthesized from this compound via a separate pathway. The activity of the  $\beta$ -oxidation pathway varies with the fatty acid concentration. This, in turn, depends on the activity of "hormone-sensitive" triacylglycerol lipase in adipose tissue that is stimulated, through cAMP-regulated phosphorylation/dephosphorylation reactions, by glucagon and epinephrine but inhibited by insulin. The fatty acid synthesis rate varies with the activity of acetyl-CoA carboxylase, which is activated by citrate and inhibited by the pathway product palmitoyl-CoA. Fatty acid synthesis is also subject to long-term regulation through alterations in the rates of synthesis of the enzymes mediating this process as stimulated by insulin and inhibited by fasting.

### 5. Citric acid cycle (Chapter 19)

The citric acid cycle oxidizes acetyl-CoA, the common degradation product of glucose, fatty acids, and ketogenic amino acids, to  $CO_2$  and  $H_2O$  with the concomitant production of NADH and  $FADH_2$ . Many glucogenic amino acids can also be oxidized via the citric acid cycle through their breakdown to one of its intermediates (Section 24-3). The activities of the citric acid cycle regulatory enzymes, citrate synthase, isocitrate dehydrogenase, and  $\alpha$ -ketoglutarate dehydrogenase, are controlled by substrate availability and feedback inhibition by cycle intermediates.

### 6. Oxidative phosphorylation (Chapter 20)

This mitochondrial pathway oxidizes NADH and  $FADH_2$  to  $NAD^+$  and FAD with the coupled synthesis of ATP. The rate of oxidative phosphorylation, which is tightly coordinated with the metabolic fluxes through glycolysis and the citric acid cycle, is largely dependent on the concentrations of ATP, ADP, and  $P_i$ .

### 7. Pentose phosphate pathway (Section 21-4)

This pathway functions to generate NADPH for use in reductive biosynthesis, as well as the nucleotide precursor ribose-5-phosphate, through the oxidation of G6P. Its flux-generating step is catalyzed by glucose-6-phosphate

dehydrogenase, which is controlled by the level of  $NADP^+$ . The ability of enzymes to distinguish between NADH, which is mainly utilized in energy metabolism, and NADPH permits energy metabolism and biosynthesis to be regulated independently.

### 8. Amino acid degradation and synthesis (Sections 24-1 through 24-5)

Excess amino acids may be degraded to common metabolic intermediates. Most of these pathways begin with an amino acid's transamination to its corresponding  $\alpha$ -keto acid with the eventual transfer of the amino group to urea via the urea cycle. Leucine and lysine are ketogenic amino acids in that they can be converted only to acetyl-CoA or acetoacetate and hence cannot be glucose precursors. The other amino acids are glucogenic in that they may be, at least in part, converted to one of the glucose precursors—pyruvate, oxaloacetate,  $\alpha$ -ketoglutarate, succinyl-CoA, or fumarate. Five amino acids are both ketogenic and glucogenic. Essential amino acids are those that an animal cannot synthesize itself; they must be obtained from plant and microbial sources. Nonessential amino acids can be synthesized by animals via pathways that are generally simpler than those synthesizing essential amino acids.

Two compounds lie at the crossroads of the foregoing metabolic pathways: acetyl-CoA and pyruvate (Fig. 25-1). Acetyl-CoA is the common degradation product of most metabolic fuels, including polysaccharides, lipids, and proteins. Its acetyl group may be oxidized to  $CO_2$  and  $H_2O$  via the citric acid cycle and oxidative phosphorylation or used to synthesize fatty acids. Pyruvate is the product of glycolysis, the dehydrogenation of lactate, and the breakdown of certain glucogenic amino acids. It may be oxidatively decarboxylated to yield acetyl-CoA, thereby committing its atoms either to oxidation or to the biosynthesis of fatty acids. Alternatively, it may be carboxylated via the pyruvate carboxylase reaction to form oxaloacetate which, in turn, either replenishes citric acid cycle intermediates or enters gluconeogenesis via phosphoenolpyruvate, thereby bypassing an irreversible step in glycolysis. Pyruvate is therefore a precursor of several amino acids as well as of glucose.

The foregoing pathways occur in specific cellular compartments. Glycolysis, glycogen synthesis and degradation, fatty acid synthesis, and the pentose phosphate pathway are largely or entirely cytosolically based, whereas fatty acid degradation, the citric acid cycle, and oxidative phosphorylation occur largely in the mitochondrion. Different phases of gluconeogenesis and amino acid degradation occur in each of these compartments. The flow of metabolites across compartment membranes is mediated, in most cases, by specific carriers that are also subject to regulation.

The enormous number of enzymatic reactions that simultaneously occur in every cell (Fig. 15-1) must be coordinated and strictly controlled to meet the cell's needs. Such


regulation occurs on many levels. Intercellular communications regulating metabolism occur via certain hormones, including epinephrine, norepinephrine, glucagon, and insulin, as well as through a series of steroid hormones known as **glucocorticoids** (whose actions are discussed in Section 34-4A). These hormonal signals trigger a variety of cellular responses, including the synthesis of second messengers such as cAMP in the short term and the modulation of protein synthesis rates in the long term. On the molecular level, the enzymatic reaction rates are controlled by phosphorylation/dephosphorylation via amplifying reaction cascades, by allosteric responses to the presence of effectors, which are usually precursors or products of the reaction pathway being controlled, and by substrate availability. The regulatory machinery of opposing catabolic and anabolic pathways is generally arranged such that these pathways are reciprocally regulated.

## 2. ORGAN SPECIALIZATION

In this section we consider how the special needs of the mammalian body organs are met and how their metabolic capabilities are coordinated to meet these needs. In particular, we discuss brain, muscle, adipose tissue, and liver (Fig. 25-2).

### A. Brain

Brain tissue has a remarkably high respiration rate. For instance, the human brain only constitutes ~2% of the adult body mass but is responsible for ~20% of its resting  $O_2$  consumption. This consumption, moreover, is independent of the state of mental activity; it varies little between sleep and the intense concentration required of, say, the study of biochemistry. Most of the brain's energy pro-



**FIGURE 25-2.** The metabolic interrelationships among brain, adipose tissue, muscle, and liver. The red arrows indicate pathways that predominate in the well-fed state when glucose, amino acids, and fatty acids are directly available from the intestines.

## **EXHIBIT G**

**DONALD VOET**

*University of Pennsylvania*

**JUDITH G. VOET**

*Swarthmore College*

**BIOCHEMISTRY**  
SECOND EDITION



**JOHN WILEY & SONS, INC.**

*New York Chichester Brisbane*

*Toronto Singapore*

Acquisitions Editor: *Nedah Rose*  
Marketing Manager: *Catherine Faduska*  
Designer: *Madelyn Lesure*  
Manufacturing Manager: *Susan Stetzer*  
Photo Researcher: *Hilary Newman*  
Illustration Coordinator: *Edward Starr*  
Illustrators: *J/B Woolsey Associates*  
Production Management: *Pamela Kennedy Oborski and Suzanne Ingrao*

Cover and Part Opening Illustrations © *Irving Geis*  
This book was set in 9.5/12 Times Roman by Progressive Information Technologies and printed and bound by Von Hoffman Press. The cover was printed by Lehigh Press Lithographers. Color separations by Lehigh Press Colortronics.

Recognizing the importance of preserving what has been written, it is a policy of John Wiley & Sons, Inc. to have books of enduring value published in the United States printed on acid-free paper, and we exert our best efforts to that end.

John Wiley & Sons, Inc., places great value on the environment and is actively involved in efforts to preserve it. Currently, paper of high enough quality to reproduce full-color art effectively contains a maximum of 10% recovered and recycled post-consumer fiber. Wherever possible, Wiley uses paper containing the maximum amount of recycled fibers. In addition, the paper in this book was manufactured by a mill whose forest management programs include sustained yield harvesting of its timberlands. Sustained yield harvesting principles ensure that the number of trees cut each year does not exceed the amount of new growth.



**TOTAL 10% RECYCLED PAPER**  
**ALL POST-CONSUMER WASTE**

Copyright © 1995, by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Sections 107 and 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

ISBN: 0-471-58651-X

Printed in the United States of America

10 9 8 7 6 5 4 3 2



*Cover Art:* Two paintings of horse heart cytochrome c by Irving Geis in which the protein is illuminated by its single iron atom. On the front cover the hydrophilic side chains are drawn in green, and on the back cover the hydrophobic side chains are drawn in orange. The paintings are based on an X-ray structure by Richard Dickerson.

inhibitor binds essentially irreversibly to any trypsin formed in the pancreas so as to inactivate it. Furthermore, the trypsin-catalyzed activation of trypsinogen (Fig. 14-26) occurs quite slowly, presumably because the unusually large negative charge of its highly evolutionarily conserved N-terminal hexapeptide repels the Asp at the back of trypsin's specificity pocket. Finally, pancreatic zymogens are stored in intracellular vesicles called **zymogen granules** whose membranous walls are thought to be resistant to enzymatic degradation.


### Zymogens Have Distorted Active Sites

Since the zymogens of trypsin, chymotrypsin, and elastase have all their catalytic residues, why aren't they enzymatically active? Comparisons of the X-ray structures of trypsinogen with that of trypsin and of chymotrypsinogen with that of chymotrypsin show that upon activation, the newly liberated N-terminal Ile 16 residue moves from the surface of the protein to an internal position, where its free cationic amino group forms an ion pair with the invariant anionic Asp 194 (Fig. 14-21). Aside from this change, however, the structures of these zymogens closely resemble those of their corresponding active enzymes. Surprisingly, this resemblance includes their catalytic triads, an observation which led to the discovery that these zymogens are actually enzymatically active, albeit at a very low level. Careful comparisons of the corresponding enzyme and zymogen structures, however, revealed the reason for this low activity: *The zymogens' specificity pockets and oxyanion holes are improperly formed such that, for example, the amide NH of chymotrypsin's Gly 193 points in the wrong direction to form a hydrogen bond with the tetrahedral intermediate (see Fig. 14-25)*. Hence, the zymogens' very low enzymatic activity arises from their reduced ability to bind substrate productively and to stabilize the tetrahedral intermediate. These observations provide further structural evidence favoring the role of transition state binding in the catalytic mechanism of serine proteases.


### disulfide (GSSG) to glutathione (GSH):



(the structures of NADP<sup>+</sup> and NADPH are indicated in Fig. 12-2). This process normally produces a GSH:GSSG ratio of over 100:1, which permits GSH to function as an intracellular reducing agent (the thermodynamics of oxidation-reduction reactions is discussed in Section 15-5). For example, the inactivation of proteins (P) that have free SH groups through the spontaneous oxidative formation of mixed disulfides



is reversed through disulfide interchange with GSH.



GSH also acts as a coenzyme in several enzymatically catalyzed reductions and plays an important role in the transport of amino acids into certain cells (Section 24-4C).


### FAD Is an Essential Redox Coenzyme

Glutathione reductase contains the electron-transfer prosthetic group **flavin adenine dinucleotide (FAD; Fig. 14-28)**. **Flavins** (substances that contain the isoalloxazine ring) can undergo two sequential one-electron transfers (Fig. 14-28), or a simultaneous two-electron transfer that bypasses the semiquinone state. The glutathione reductase reaction involves the simultaneous transfer of two electrons so that,

## 4. GLUTATHIONE REDUCTASE

Lysozyme and the serine proteases all catalyze hydrolytic reactions. In contrast, the third enzyme that we shall consider in mechanistic detail, **glutathione reductase**, catalyzes an oxidation-reduction reaction. Such reactions are extremely important in metabolic processes. We have chosen to study glutathione reductase, which sequentially catalyzes several electron-transfer processes, because it is one of the few such enzymes in which the pathway of electron flow has been well characterized.

Glutathione reductase is a nearly ubiquitous enzyme that catalyzes the NADPH-dependent reduction of glutathione



**FIGURE 14-28.** The molecular formula and reactions of the coenzyme flavin adenine dinucleotide (FAD). The term “flavin” is synonymous with the isoalloxazine ring system. The d-ribitol residue is derived from the alcohol of the sugar d-ribose. FAD may be half-reduced to the stable radical FADH<sup>•</sup> or fully

reduced to FADH<sub>2</sub> (boxes). Consequently, different FAD-containing enzymes cycle between different oxidation states of FAD. FAD is usually tightly bound to its enzymes so that this coenzyme normally is a prosthetic group rather than a cosubstrate as is the case, for example, with NAD<sup>+</sup>.


in this case, the FAD never assumes its radical form. The oxidation state of the flavin in a **flavoprotein** (flavin-containing protein) is readily established from its characteristic UV-visible spectrum: FAD is an intense yellow, whereas FADH<sub>2</sub> is pale yellow.

Humans and other higher animals are unable to synthesize the isoalloxazine component of flavins, so they must obtain this substance from their diets, for example, in the form of **riboflavin** (vitamin B<sub>2</sub>) (Fig. 14-28). Riboflavin deficiency is quite rare in humans, in part because of the tight binding of flavin prosthetic groups to their apoenzymes. The symptoms of riboflavin deficiency, which are associated with general malnutrition or bizarre diets, include an inflamed tongue, lesions in the corners of the mouth, and dermatitis.


#### Glutathione Reductase Catalyzes a Two-Stage Reaction

Glutathione reductase from human erythrocytes is a dimer of identical 478-residue subunits that are covalently linked by an intersubunit disulfide bond. In the absence of


GSSG, the enzyme catalyzes the first stage of a two-stage reaction:



where E represents fully oxidized glutathione reductase and EH<sub>2</sub> is a stable two-electron reduced intermediate whose chemical nature we shall presently discuss. Upon subsequent addition of GSSG, EH<sub>2</sub> reacts to form products and complete the catalytic cycle.



The glutathione reductase reaction is more complex than these overall reactions suggest. Vincent Massey and Charles Williams demonstrated that *oxidized glutathione reductase (E) contains a “redox-active” disulfide bond, which in EH<sub>2</sub> has accepted an electron pair through bond cleavage to form a dithiol*.



## APPENDIX B



A service of the National Library of Medicine  
and the National Institutes of Health

My NCBI  
[Sign In] [Re]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

B

Search | PubMed

for nadh

Go

Clear

Save S...

Limits   Preview/Index   History   Clipboard   Details

Field: **Title, Limits: Publication Date from 2002 to 2002**

Display **Summary**

Show 200

Sort by

Send to

All: 124   Review: 6

Items 1 - 124 of 124

One page.

1: [Haldimann P, Tsimilli-Michael M.](#)

Related Articles, Links

Mercury inhibits the non-photochemical reduction of plastoquinone by exogenous NADPH and NADH: evidence from measurements of the polyphasic chlorophyll a fluorescence rise in spinach chloroplasts.  
Photosynth Res. 2002;74(1):37-50.  
PMID: 16228543 [PubMed - as supplied by publisher]

2: [Pagala VR, Park J, Reed DW, Hartzell PL.](#)

Related Articles, Links

Cellular localization of D-lactate dehydrogenase and NADH oxidase from *Archaeoglobus fulgidus*.  
Archaea. 2002 Sep;1(2):95-104.  
PMID: 15803647 [PubMed - indexed for MEDLINE]

3: [Kedar PS, Colah RB, Ghosh K, Mohanty D.](#)

Related Articles, Links

Congenital methemoglobinemia due to NADH-methemoglobin reductase deficiency in three Indian families.  
Haematologia (Budap). 2002;32(4):543-9.  
PMID: 12803131 [PubMed - indexed for MEDLINE]

4: [Averet N, Aguilaniu H, Bunoust O, Gustafsson L, Rigoulet M.](#)

Related Articles, Links

NADH is specifically channeled through the mitochondrial porin channel in *Saccharomyces cerevisiae*.  
J Bioenerg Biomembr. 2002 Dec;34(6):499-506.  
PMID: 12678441 [PubMed - indexed for MEDLINE]

5: [Birkmayer JG, Nadlinger K.](#)

Related Articles, Links

Safety of stabilized, orally absorbable, reduced nicotinamide adenine dinucleotide (NADH): a 26-week oral tablet administration of ENADA/NADH for chronic toxicity study in rats.  
Drugs Exp Clin Res. 2002;28(5):185-92.  
PMID: 12635493 [PubMed - indexed for MEDLINE]

6: [Berrios-Rivera SJ, San KY, Bennett GN.](#)

Related Articles, Links

The effect of NAPRTase overexpression on the total levels of NAD, the NADH/NAD<sup>+</sup> ratio, and the distribution of metabolites in *Escherichia coli*.  
Metab Eng. 2002 Jul;4(3):238-47.  
PMID: 12616693 [PubMed - indexed for MEDLINE]

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy   
E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

7: [Berrios-Rivera SJ, Bennett GN, San KY.](#) Related Articles, Links  
 The effect of increasing NADH availability on the redistribution of metabolic fluxes in *Escherichia coli* chemostat cultures.  
Metab Eng. 2002 Jul;4(3):230-7.  
PMID: 12616692 [PubMed - indexed for MEDLINE]

8: [Berrios-Rivera SJ, Bennett GN, San KY.](#) Related Articles, Links  
 Metabolic engineering of *Escherichia coli*: increase of NADH availability by overexpressing an NAD(+) -dependent formate dehydrogenase.  
Metab Eng. 2002 Jul;4(3):217-29.  
PMID: 12616691 [PubMed - indexed for MEDLINE]

9: [Zakharova NV, Zharova TV.](#) Related Articles, Links  
 Kinetic mechanism of mitochondrial NADH:ubiquinone oxidoreductase interaction with nucleotide substrates of the transhydrogenase reaction.  
Biochemistry (Mosc). 2002 Dec;67(12):1395-404.  
PMID: 12600270 [PubMed - indexed for MEDLINE]

10: [Nakano K, Takeo T, Sato T, Suga S, Eto K, Kadokawa T, Wakui M.](#) Related Articles, Links  
 Role of mitochondrial NADH shuttle system in acute amylase secretion by acetylcholine from mouse pancreatic acinar cells.  
Tohoku J Exp Med. 2002 Nov;198(3):151-62.  
PMID: 12597242 [PubMed - indexed for MEDLINE]

11: [Lo HC, Fish RH.](#) Related Articles, Links  
 Biomimetic NAD(+) models for tandem cofactor regeneration, horse liver alcohol dehydrogenase recognition of 1,4-NADH derivatives, and chiral synthesis.  
Angew Chem Int Ed Engl. 2002 Feb 1;41(3):478-81. No abstract available.  
PMID: 12491384 [PubMed - indexed for MEDLINE]

12: [Banta S, Anderson S.](#) Related Articles, Links  
 Verification of a novel NADH-binding motif: combinatorial mutagenesis of three amino acids in the cofactor-binding pocket of *Corynebacterium* 2,5-diketo-D-gluconic acid reductase.  
J Mol Evol. 2002 Dec;55(6):623-31.  
PMID: 12486521 [PubMed - indexed for MEDLINE]

13: [Okinaka Y, Yang CH, Herman E, Kinney A, Keen NT.](#) Related Articles, Links  
 The P34 syringolide elicitor receptor interacts with a soybean photorespiration enzyme, NADH-dependent hydroxypyruvate reductase.  
Mol Plant Microbe Interact. 2002 Dec;15(12):1213-8.  
PMID: 12481993 [PubMed - indexed for MEDLINE]

14: [Harmych S, Arnette R, Komuniecki R.](#) Related Articles, Links  
 Role of dihydrolipoyl dehydrogenase (E3) and a novel E3-binding protein in the NADH sensitivity of the pyruvate dehydrogenase complex from anaerobic mitochondria of the parasitic nematode, *Ascaris suum*.  
Mol Biochem Parasitol. 2002 Nov-Dec;125(1-2):135-46.  
PMID: 12467981 [PubMed - indexed for MEDLINE]

15: [Fukuzumi S, Inada O, Suenobu T.](#) Related Articles, Links

Direct detection of radical cations of NADH analogues.  
J Am Chem Soc. 2002 Dec 11;124(49):14538-9. No abstract available.  
PMID: 12465955 [PubMed - indexed for MEDLINE]

16: [Mathiesen C, Hagerhall C.](#) [Related Articles](#), [Links](#)

Transmembrane topology of the NuoL, M and N subunits of NADH:quinone oxidoreductase and their homologues among membrane-bound hydrogenases and bona fide antiporters.  
Biochim Biophys Acta. 2002 Dec 2;1556(2-3):121-32.  
PMID: 12460669 [PubMed - indexed for MEDLINE]

17: [Bogachev AV, Bertsova YV, Ruuge EK, Wikstrom M, Verkhovsky MI.](#) [Related Articles](#), [Links](#)

Kinetics of the spectral changes during reduction of the Na<sup>+</sup>-motive NADH:quinone oxidoreductase from *Vibrio harveyi*.  
Biochim Biophys Acta. 2002 Dec 2;1556(2-3):113-20.  
PMID: 12460668 [PubMed - indexed for MEDLINE]

18: [Kimura S, Kawamura M, Iyanagi T.](#) [Related Articles](#), [Links](#)

Role of Thr(66) in porcine NADH-cytochrome b5 reductase in catalysis and control of the rate-limiting step in electron transfer.  
J Biol Chem. 2003 Feb 7;278(6):3580-9. Epub 2002 Nov 28.  
PMID: 12459552 [PubMed - indexed for MEDLINE]

19: [Nixon JE, Wang A, Field J, Morrison HG, McArthur AG, Sogin ML, Loftus BJ, Samuelson J.](#) [Related Articles](#), [Links](#)

Evidence for lateral transfer of genes encoding ferredoxins, nitroreductases, NADH oxidase, and alcohol dehydrogenase 3 from anaerobic prokaryotes to *Giardia lamblia* and *Entamoeba histolytica*.  
Eukaryot Cell. 2002 Apr;1(2):181-90.  
PMID: 12455953 [PubMed - indexed for MEDLINE]

20: [Neves AR, Ramos A, Costa H, van Swam II, Hogenholtz J, Kleerebezem M, de Vos W, Santos H.](#) [Related Articles](#), [Links](#)

Effect of different NADH oxidase levels on glucose metabolism by *Lactococcus lactis*: kinetics of intracellular metabolite pools determined by in vivo nuclear magnetic resonance.  
Appl Environ Microbiol. 2002 Dec;68(12):6332-42.  
PMID: 12450858 [PubMed - indexed for MEDLINE]

21: [Morre DJ, Penel C, Greppin H, Morre DM.](#) [Related Articles](#), [Links](#)

The plasma membrane-associated NADH oxidase of spinach leaves responds to blue light.  
Int J Plant Sci. 2002 Jul;163(4):543-7.  
PMID: 12448422 [PubMed - indexed for MEDLINE]

22: [Flemming D, Hellwig P, Friedrich T.](#) [Related Articles](#), [Links](#)

Involvement of tyrosines 114 and 139 of subunit NuoB in the proton pathway around cluster N2 in *Escherichia coli* NADH:ubiquinone oxidoreductase.  
J Biol Chem. 2003 Jan 31;278(5):3055-62. Epub 2002 Nov 20.  
PMID: 12446673 [PubMed - indexed for MEDLINE]

23: [Kumar P, Pai K, Pandey HP, Sundar S.](#) [Related Articles](#), [Links](#)

NADH-oxidase, NADPH-oxidase and myeloperoxidase activity of

 visceral leishmaniasis patients.  
J Med Microbiol. 2002 Oct;51(10):832-6.  
PMID: 12435061 [PubMed - indexed for MEDLINE]

24: [Harrison M, Singh SM.](#) [Related Articles](#), [Links](#)

 Genetics and differential expression of NADH:ubiquinone oxidoreductase B8 subunit in brains of genetic strains of mice differing in voluntary alcohol consumption.  
Biochim Biophys Acta. 2002 Dec 12;1579(2-3):164-72.  
PMID: 12427551 [PubMed - indexed for MEDLINE]

25: [Holtz KM, Rockwell S, Tomasz M, Sartorelli AC.](#) [Related Articles](#), [Links](#)

 Nuclear overexpression of NADH:cytochrome b5 reductase activity increases the cytotoxicity of mitomycin C (MC) and the total number of MC-DNA adducts in Chinese hamster ovary cells.  
J Biol Chem. 2003 Feb 14;278(7):5029-34. Epub 2002 Nov 6.  
PMID: 12424239 [PubMed - indexed for MEDLINE]

26: [Bandeiras TM, Salgueiro C, Kletzin A, Gomes CM, Teixeira M.](#) [Related Articles](#), [Links](#)

 Acidianus ambivalens type-II NADH dehydrogenase: genetic characterisation and identification of the flavin moiety as FMN.  
FEBS Lett. 2002 Nov 6;531(2):273-7.  
PMID: 12417325 [PubMed - indexed for MEDLINE]

27: [Hanley PJ, Ray J, Brandt U, Daut J.](#) [Related Articles](#), [Links](#)

 Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria.  
J Physiol. 2002 Nov 1;544(Pt 3):687-93.  
PMID: 12411515 [PubMed - indexed for MEDLINE]

28: [Reichenbach-Klinke R, Kruppa M, Konig B.](#) [Related Articles](#), [Links](#)

 NADH model systems functionalized with Zn(II)-cyclen as flavin binding site-structure dependence of the redox reaction within reversible aggregates.  
J Am Chem Soc. 2002 Nov 6;124(44):12999-3007.  
PMID: 12405826 [PubMed - indexed for MEDLINE]

29: [Nadlinger K, Westerthaler W, Storga-Tomic D, Birkmayer JG.](#) [Related Articles](#), [Links](#)

 Extracellular metabolism of NADH by blood cells correlates with intracellular ATP levels.  
Biochim Biophys Acta. 2002 Nov 14;1573(2):177-82.  
PMID: 12399028 [PubMed - indexed for MEDLINE]

30: [Vasse JL, Levacher V, Bourguignon J, Dupas G.](#) [Related Articles](#), [Links](#)

 Atropoisomeric quinolinium salt promoting the access to both enantiomeric forms of methyl mandelate: a versatile NADH mimic.  
Chem Commun (Camb). 2002 Oct 7;(19):2256-7.  
PMID: 12398004 [PubMed - indexed for MEDLINE]

31: [Percy MJ, Gillespie MJ, Savage G, Hughes AE, McMullin MF, Lappin TR.](#) [Related Articles](#), [Links](#)

 Familial idiopathic methemoglobinemia revisited: original cases reveal 2 novel mutations in NADH-cytochrome b5 reductase.  
Blood. 2002 Nov 15;100(10):3447-9. Epub 2002 Jul 5.

PMID: 12393396 [PubMed - indexed for MEDLINE]

32: [Cocco T, Cutecchia G, Montedoro G, Lorusso M.](#) [Related Articles](#), [Links](#)

 The antihypertensive drug carvedilol inhibits the activity of mitochondrial NADH-ubiquinone oxidoreductase.  
J Bioenerg Biomembr. 2002 Aug;34(4):251-8.  
PMID: 12392188 [PubMed - indexed for MEDLINE]

33: [Liu FQ, Zhang JR.](#) [Related Articles](#), [Links](#)

 Effect of NADH against liver cell line L02 apoptosis induced by UVB irradiation.  
Di Yi Jun Yi Da Xue Xue Bao. 2002 Mar;22(3):232-4.  
PMID: 12390773 [PubMed - indexed for MEDLINE]

34: [Birkmayer GD, Kay GG, Vurre E.](#) [Related Articles](#), [Links](#)

 [Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit]  
Wien Med Wochenschr. 2002;112(17-18):450-4. German.  
PMID: 12385067 [PubMed - indexed for MEDLINE]

35: [Elmore CL, Porter TD.](#) [Related Articles](#), [Links](#)

 Modification of the nucleotide cofactor-binding site of cytochrome P-450 reductase to enhance turnover with NADH in Vivo.  
J Biol Chem. 2002 Dec 13;277(50):48960-4. Epub 2002 Oct 14.  
PMID: 12381719 [PubMed - indexed for MEDLINE]

36: [Prasad GS, Wahlberg M, Sridhar V, Sundaresan V, Yamaguchi M, Hatefi Y, Stout CD.](#) [Related Articles](#), [Links](#)

 Crystal structures of transhydrogenase domain I with and without bound NADH.  
Biochemistry. 2002 Oct 22;41(42):12745-54.  
PMID: 12379117 [PubMed - indexed for MEDLINE]

37: [Tan C, Tuch BE, Tu J, Brown SA.](#) [Related Articles](#), [Links](#)

 Role of NADH shuttles in glucose-induced insulin secretion from fetal beta-cells.  
Diabetes. 2002 Oct;51(10):2989-96. Erratum in: Diabetes 2003 Jan;52(1):224.  
PMID: 12351438 [PubMed - indexed for MEDLINE]

38: [Drose S, Zwicker K, Brandt U.](#) [Related Articles](#), [Links](#)

 Full recovery of the NADH:ubiquinone activity of complex I (NADH:ubiquinone oxidoreductase) from *Yarrowia lipolytica* by the addition of phospholipids.  
Biochim Biophys Acta. 2002 Oct 3;1556(1):65-72.  
PMID: 12351219 [PubMed - indexed for MEDLINE]

39: [Maklashina E, Sher Y, Zhou HZ, Gray MO, Karliner JS, Cecchini G.](#) [Related Articles](#), [Links](#)

 Effect of anoxia/reperfusion on the reversible active/de-active transition of NADH-ubiquinone oxidoreductase (complex I) in rat heart.  
Biochim Biophys Acta. 2002 Oct 3;1556(1):6-12.  
PMID: 12351213 [PubMed - indexed for MEDLINE]

40: [Fang J, Beattie DS.](#) [Related Articles](#), [Links](#)

**41:** [Eto K, Kadokawa T.](#) [Related Articles](#), [Links](#)  
Rotenone-insensitive NADH dehydrogenase is a potential source of superoxide in procyclic *Trypanosoma brucei* mitochondria.  
*Mol Biochem Parasitol.* 2002 Aug 28;123(2):135-42.  
PMID: 12270629 [PubMed - indexed for MEDLINE]

**42:** [Seo BB, Nakamaru-Ogiso E, Flotte TR, Yagi T, Matsuno-Yagi A.](#) [Related Articles](#), [Links](#)  
A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition.  
*Mol Ther.* 2002 Sep;6(3):336-41. Erratum in: *Mol Ther.* 2003 Jun;7(6):859.  
PMID: 12231169 [PubMed - indexed for MEDLINE]

**43:** [Yano T.](#) [Related Articles](#), [Links](#)  
The energy-transducing NADH: quinone oxidoreductase, complex I.  
*Mol Aspects Med.* 2002 Oct;23(5):345-68. Review.  
PMID: 12231006 [PubMed - indexed for MEDLINE]

**44:** [Denicola A, Rubbo H, Haden L, Turrens JF.](#) [Related Articles](#), [Links](#)  
Extramitochondrial localization of NADH-fumarate reductase in trypanosomatids.  
*Comp Biochem Physiol B Biochem Mol Biol.* 2002 Sep;133(1):23-7.  
PMID: 12223208 [PubMed - indexed for MEDLINE]

**45:** [Videira A, Duarte M.](#) [Related Articles](#), [Links](#)  
From NADH to ubiquinone in *Neurospora* mitochondria.  
*Biochim Biophys Acta.* 2002 Sep 10;1555(1-3):187-91. Review.  
PMID: 12206913 [PubMed - indexed for MEDLINE]

**46:** [Olek RA, Antosiewicz J, Caulini GC, Falcioni G.](#) [Related Articles](#), [Links](#)  
Effect of NADH on the redox state of human hemoglobin.  
*Clin Chim Acta.* 2002 Oct;324(1-2):129-34.  
PMID: 12204434 [PubMed - indexed for MEDLINE]

**47:** [Buchner M, Huber R, Sturchler-Pierrat C, Staufenbiel M, Riepe MW.](#) [Related Articles](#), [Links](#)  
Impaired hypoxic tolerance and altered protein binding of NADH in presymptomatic APP23 transgenic mice.  
*Neuroscience.* 2002;114(2):285-9.  
PMID: 12204198 [PubMed - indexed for MEDLINE]

**48:** [Huang GL, Zhang G, Gao Y, Zhu JW.](#) [Related Articles](#), [Links](#)  
[Role of NADH-cytochrome b(5) reductase in biosynthesis of thyroid hydrogen peroxide]  
*Sheng Li Xue Bao.* 2002 Aug 25;54(4):349-53. Chinese.  
PMID: 12195287 [PubMed - in process]

**49:** [Kotlyar AB, Borovok N.](#) [Related Articles](#), [Links](#)  
NADH oxidation and NAD<sup>+</sup> reduction catalysed by tightly coupled inside-out vesicles from *Paracoccus denitrificans*.  
*Eur J Biochem.* 2002 Aug;269(16):4020-4.

PMID: 12180978 [PubMed - indexed for MEDLINE]

**50:** [Rapisarda VA, Chehin RN, De Las Rivas J, Rodriguez-Montelongo L, Farias RN, Massa EM.](#) [Related Articles](#), [Links](#)

 Evidence for Cu(I)-thiolate ligation and prediction of a putative copper-binding site in the *Escherichia coli* NADH dehydrogenase-2. *Arch Biochem Biophys.* 2002 Sep 1;405(1):87-94. PMID: 12176061 [PubMed - indexed for MEDLINE]

**51:** [Magnitsky S, Toulokhonova L, Yano T, Sled VD, Hagerhall C, Grivennikova VG, Burbaev DS, Vinogradov AD, Ohnishi T.](#) [Related Articles](#), [Links](#)

 EPR characterization of ubisemiquinones and iron-sulfur cluster N2, central components of the energy coupling in the NADH-ubiquinone oxidoreductase (complex I) in situ. *J Bioenerg Biomembr.* 2002 Jun;34(3):193-208. PMID: 12171069 [PubMed - indexed for MEDLINE]

**52:** [Noda M, Yamashita S, Takahashi N, Eto K, Shen LM, Izumi K, Daniel S, Tsubamoto Y, Nemoto T, Iino M, Kasai H, Sharp GW, Kadokawa T.](#) [Related Articles](#), [Links](#)

 Switch to anaerobic glucose metabolism with NADH accumulation in the beta-cell model of mitochondrial diabetes. Characteristics of betaHC9 cells deficient in mitochondrial DNA transcription. *J Biol Chem.* 2002 Nov 1;277(44):41817-26. Epub 2002 Aug 6. PMID: 12169697 [PubMed - indexed for MEDLINE]

**53:** [Martin-Romero FJ, Garcia-Martin E, Gutierrez-Merino C.](#) [Related Articles](#), [Links](#)

 Inhibition of oxidative stress produced by plasma membrane NADH oxidase delays low-potassium-induced apoptosis of cerebellar granule cells. *J Neurochem.* 2002 Aug;82(3):705-15. PMID: 12153494 [PubMed - indexed for MEDLINE]

**54:** [Martin-Romero FJ, Gutierrez-Martin Y, Henao F, Gutierrez-Merino C.](#) [Related Articles](#), [Links](#)

 The NADH oxidase activity of the plasma membrane of synaptosomes is a major source of superoxide anion and is inhibited by peroxynitrite. *J Neurochem.* 2002 Aug;82(3):604-14. PMID: 12153484 [PubMed - indexed for MEDLINE]

**55:** [Zu Y, Di Bernardo S, Yagi T, Hirst J.](#) [Related Articles](#), [Links](#)

 Redox properties of the [2Fe-2S] center in the 24 kDa (NQO2) subunit of NADH:ubiquinone oxidoreductase (complex I). *Biochemistry.* 2002 Aug 6;41(31):10056-69. PMID: 12146970 [PubMed - indexed for MEDLINE]

**56:** [Besteiro S, Biran M, Biteau N, Coustou V, Baltz T, Canioni P, Bringaud F.](#) [Related Articles](#), [Links](#)

 Succinate secreted by *Trypanosoma brucei* is produced by a novel and unique glycosomal enzyme, NADH-dependent fumarate reductase. *J Biol Chem.* 2002 Oct 11;277(41):38001-12. Epub 2002 Jul 22. PMID: 12138089 [PubMed - indexed for MEDLINE]

**57:** [Zakharova NV.](#) [Related Articles](#), [Links](#)

 Kinetics of the transhydrogenase reaction catalyzed by mitochondrial NADH:ubiquinone oxidoreductase (complex I).

Biochemistry (Mosc). 2002 Jun;67(6):651-61.  
PMID: 12126472 [PubMed - indexed for MEDLINE]

**58:** [Anderson RE, Meyer FB.](#) Related Articles, Links

In vivo fluorescent imaging of NADH redox state in brain.  
Methods Enzymol. 2002;352:482-94. No abstract available.  
PMID: 12125373 [PubMed - indexed for MEDLINE]

**59:** [Brandes R, Bers DM.](#) Related Articles, Links

 Simultaneous measurements of mitochondrial NADH and Ca(2+) during increased work in intact rat heart trabeculae.  
Biophys J. 2002 Aug;83(2):587-604.  
PMID: 12124250 [PubMed - indexed for MEDLINE]

**60:** [Barquera B, Zhou W, Morgan JE, Gennis RB.](#) Related Articles, Links

 Riboflavin is a component of the Na+-pumping NADH-quinone oxidoreductase from *Vibrio cholerae*.  
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10322-4. Epub 2002 Jul 16.  
PMID: 12122213 [PubMed - indexed for MEDLINE]

**61:** [Camacho Carvajal MM, Wijfjes AH, Mulders IH, Lugtenberg BJ, Bloemberg GV.](#) Related Articles, Links

 Characterization of NADH dehydrogenases of *Pseudomonas fluorescens* WCS365 and their role in competitive root colonization.  
Mol Plant Microbe Interact. 2002 Jul;15(7):662-71.  
PMID: 12118882 [PubMed - indexed for MEDLINE]

**62:** [Zhang L, Kudo T, Takaya N, Shoun H.](#) Related Articles, Links

 The B' helix determines cytochrome P450nor specificity for the electron donors NADH and NADPH.  
J Biol Chem. 2002 Sep 13;277(37):33842-7. Epub 2002 Jul 8.  
PMID: 12105197 [PubMed - indexed for MEDLINE]

**63:** [McDonough JA, Bhattacherjee V, Sadlon T, Hostetter MK.](#) Related Articles, Links

 Involvement of *Candida albicans* NADH dehydrogenase complex I in filamentation.  
Fungal Genet Biol. 2002 Jul;36(2):117-27.  
PMID: 12081465 [PubMed - indexed for MEDLINE]

**64:** [Yeh JI, Claiborne A.](#) Related Articles, Links

 Crystal structures of oxidized and reduced forms of NADH peroxidase.  
Methods Enzymol. 2002;353:44-54.  
PMID: 12078517 [PubMed - indexed for MEDLINE]

**65:** [Rex A, Hentschke MP, Fink H.](#) Related Articles, Links

 Bioavailability of reduced nicotinamide-adenine-dinucleotide (NADH) in the central nervous system of the anaesthetized rat measured by laser-induced fluorescence spectroscopy.  
Pharmacol Toxicol. 2002 Apr;90(4):220-5.  
PMID: 12076318 [PubMed - indexed for MEDLINE]

**66:** [Taylor LM, Andrew Aquilina J, Jamie JF, Truscott RJ.](#) Related Articles, Links

 Glutathione and NADH, but not ascorbate, protect lens proteins from modification by UV filters.

Exp Eye Res. 2002 Apr;74(4):503-11.  
PMID: 12076094 [PubMed - indexed for MEDLINE]

67: [Valdez LB, Actis-Goretta L, Boveris A.](#) [Related Articles](#), [Links](#)

 Polyphenols in red wines prevent NADH oxidation induced by peroxynitrite.  
Ann N Y Acad Sci. 2002 May;957:274-8.  
PMID: 12074980 [PubMed - indexed for MEDLINE]

68: [Boveris A, Valdez L, Alvarez S.](#) [Related Articles](#), [Links](#)

 Inhibition by wine polyphenols of peroxynitrite-initiated chemiluminescence and NADH oxidation.  
Ann N Y Acad Sci. 2002 May;957:90-102. Review.  
PMID: 12074964 [PubMed - indexed for MEDLINE]

69: [Herles C, Braune A, Blaut M.](#) [Related Articles](#), [Links](#)

 Purification and characterization of an NADH oxidase from *Eubacterium ramulus*.  
Arch Microbiol. 2002 Jul;178(1):71-4. Epub 2002 May 7.  
PMID: 12070772 [PubMed - indexed for MEDLINE]

70: [Muhlenhoff U, Richhardt N, Gerber J, Lill R.](#) [Related Articles](#), [Links](#)

 Characterization of iron-sulfur protein assembly in isolated mitochondria. A requirement for ATP, NADH, and reduced iron.  
J Biol Chem. 2002 Aug 16;277(33):29810-6. Epub 2002 Jun 13.  
PMID: 12065597 [PubMed - indexed for MEDLINE]

71: [Riess ML, Camara AK, Chen Q, Novalija E, Rhodes SS, Stowe DF.](#) [Related Articles](#), [Links](#)

 Altered NADH and improved function by anesthetic and ischemic preconditioning in guinea pig intact hearts.  
Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H53-60.  
PMID: 12063274 [PubMed - indexed for MEDLINE]

72: [Svensson AS, Johansson FI, Moller IM, Rasmussen AG.](#) [Related Articles](#), [Links](#)

 Cold stress decreases the capacity for respiratory NADH oxidation in potato leaves.  
FEBS Lett. 2002 Apr 24;517(1-3):79-82.  
PMID: 12062413 [PubMed - indexed for MEDLINE]

73: [Hayashi M, Shibata N, Nakayama Y, Yoshikawa K, Unemoto T.](#) [Related Articles](#), [Links](#)

 Korormicin insensitivity in *Vibrio alginolyticus* is correlated with a single point mutation of Gly-140 in the NqrB subunit of the Na<sup>(+)</sup>-translocating NADH-quinone reductase.  
Arch Biochem Biophys. 2002 May 15;401(2):173-7.  
PMID: 12054467 [PubMed - indexed for MEDLINE]

74: [Duarte M, Populo H, Videira A, Friedrich T, Schulte U.](#) [Related Articles](#), [Links](#)

 Disruption of iron-sulphur cluster N2 from NADH: ubiquinone oxidoreductase by site-directed mutagenesis.  
Biochem J. 2002 Jun 15;364(Pt 3):833-9.  
PMID: 12049648 [PubMed - indexed for MEDLINE]

75: [Jensen Jr KA Jr, Ryan ZC, Vanden Wymelenberg A, Cullen D, Hammel KE.](#) [Related Articles](#), [Links](#)

 An NADH:quinone oxidoreductase active during biodegradation by the brown-rot basidiomycete *Gloeophyllum trabeum*.  
Appl Environ Microbiol. 2002 Jun;68(6):2699-703.  
PMID: 12039722 [PubMed - indexed for MEDLINE]

76: [Raijmakers MT, Roes EM, Steegers EA, Peters WH.](#) [Related Articles](#), [Links](#)

 The C242T-polymorphism of the NADPH/NADH oxidase gene p22phox subunit is not associated with pre-eclampsia.  
J Hum Hypertens. 2002 Jun;16(6):423-5.  
PMID: 12037698 [PubMed - indexed for MEDLINE]

77: [Deguchi T, Matsubara M, Nishida T.](#) [Related Articles](#), [Links](#)

 NADH oxidation by manganese peroxidase with or without alpha-hydroxy acid.  
Biosci Biotechnol Biochem. 2002 Apr;66(4):717-21.  
PMID: 12036041 [PubMed - indexed for MEDLINE]

78: [Hammen PK, Allali-Hassani A, Hallenga K, Hurley TD, Weiner H.](#) [Related Articles](#), [Links](#)

 Multiple conformations of NAD and NADH when bound to human cytosolic and mitochondrial aldehyde dehydrogenase.  
Biochemistry. 2002 Jun 4;41(22):7156-68.  
PMID: 12033950 [PubMed - indexed for MEDLINE]

79: [Pahlman IL, Larsson C, Averet N, Bunoust O, Boubekr S, Gustafsson L, Rigoulet M.](#) [Related Articles](#), [Links](#)

 Kinetic regulation of the mitochondrial glycerol-3-phosphate dehydrogenase by the external NADH dehydrogenase in *Saccharomyces cerevisiae*.  
J Biol Chem. 2002 Aug 2;277(31):27991-5. Epub 2002 May 24.  
PMID: 12032156 [PubMed - indexed for MEDLINE]

80: [Batchelor RH, Zhou M.](#) [Related Articles](#), [Links](#)

 A resorufin-based fluorescent assay for quantifying NADH.  
Anal Biochem. 2002 Jun 1;305(1):118-9. No abstract available.  
PMID: 12018954 [PubMed - indexed for MEDLINE]

81: [Nakashima Y, Shinzawa-Itoh K, Watanabe K, Naoki K, Hano N, Yoshikawa S.](#) [Related Articles](#), [Links](#)

 The second coenzyme Q1 binding site of bovine heart NADH: coenzyme Q oxidoreductase.  
J Bioenerg Biomembr. 2002 Apr;34(2):89-94.  
PMID: 12018892 [PubMed - indexed for MEDLINE]

82: [Murata M, Kawanishi S.](#) [Related Articles](#), [Links](#)

 Oxidation of 5'-site guanine at GG and GGG sequences induced by a metabolite of carcinogenic heterocyclic amine PhIP in the presence of Cu (II) and NADH.  
Carcinogenesis. 2002 May;23(5):855-60.  
PMID: 12016160 [PubMed - indexed for MEDLINE]

83: [Miki T.](#) [Related Articles](#), [Links](#)

 [Mitochondrial complex I (NADH-ubiquinone oxidoreductase)]  
Nippon Rinsho. 2002 Apr;60 Suppl 4:135-8. Review. Japanese. No abstract available.  
PMID: 12013836 [PubMed - indexed for MEDLINE]

84: [Neves AR, Ventura R, Mansour N, Shearman C, Gasson MJ, Maycock C, Ramos A, Santos H.](#) Related Articles, Links  
 Is the glycolytic flux in *Lactococcus lactis* primarily controlled by the redox charge? Kinetics of NAD(+) and NADH pools determined in vivo by 13C NMR.  
*J Biol Chem.* 2002 Aug 2;277(31):28088-98. Epub 2002 May 13.  
PMID: 12011086 [PubMed - indexed for MEDLINE]

85: [Ellis EA, Guberski DL, Hutson B, Grant MB.](#) Related Articles, Links  
 Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR rat.  
*Nitric Oxide.* 2002 May;6(3):295-304.  
PMID: 12009847 [PubMed - indexed for MEDLINE]

86: [Bartlett PN, Simon E, Toh CS.](#) Related Articles, Links  
 Modified electrodes for NADH oxidation and dehydrogenase-based biosensors.  
*Bioelectrochemistry.* 2002 May 15;56(1-2):117-22.  
PMID: 12009456 [PubMed - indexed for MEDLINE]

87: [Munteanu FD, Mano N, Kuhn A, Gorton L.](#) Related Articles, Links  
 Mediator-modified electrodes for catalytic NADH oxidation: high rate constants at interesting overpotentials.  
*Bioelectrochemistry.* 2002 May 15;56(1-2):67-72.  
PMID: 12009446 [PubMed - indexed for MEDLINE]

88: [Mayr P, Nidetzky B.](#) Related Articles, Links  
 Catalytic reaction profile for NADH-dependent reduction of aromatic aldehydes by xylose reductase from *Candida tenuis*.  
*Biochem J.* 2002 Sep 15;366(Pt 3):889-99.  
PMID: 12003638 [PubMed - indexed for MEDLINE]

89: [Sambongi Y, Nitta H, Ichihashi K, Futai M, Ueda I.](#) Related Articles, Links  
 A novel water-soluble Hantzsch 1,4-dihydropyridine compound that functions in biological processes through NADH regeneration.  
*J Org Chem.* 2002 May 17;67(10):3499-501.  
PMID: 12003566 [PubMed - indexed for MEDLINE]

90: [Li N, Yi FX, Spurrier JL, Bobrowitz CA, Zou AP.](#) Related Articles, Links  
 Production of superoxide through NADH oxidase in thick ascending limb of Henle's loop in rat kidney.  
*Am J Physiol Renal Physiol.* 2002 Jun;282(6):F1111-9.  
PMID: 11997328 [PubMed - indexed for MEDLINE]

91: [Itoh N, Matsuda M, Mabuchi M, Dairi T, Wang J.](#) Related Articles, Links  
 Chiral alcohol production by NADH-dependent phenylacetaldehyde reductase coupled with in situ regeneration of NADH.  
*Eur J Biochem.* 2002 May;269(9):2394-402.  
PMID: 11985623 [PubMed - indexed for MEDLINE]

92: [Krungkrai J, Kanchanarithisak R, Krungkrai SR, Rochanakij S.](#) Related Articles, Links  
 Mitochondrial NADH dehydrogenase from *Plasmodium falciparum* and *Plasmodium berghei*.

Exp Parasitol. 2002 Jan;100(1):54-61.  
PMID: 11971654 [PubMed - indexed for MEDLINE]

93: [Morre DJ.](#)

[Related Articles](#), [Links](#)

 Preferential inhibition of the plasma membrane NADH oxidase (NOX) activity by diphenyleneiodonium chloride with NADPH as donor.  
Antioxid Redox Signal. 2002 Feb;4(1):207-12.  
PMID: 11970854 [PubMed - indexed for MEDLINE]

94: [O'Flaherty CM, Beorlegui NB, Beconi MT.](#)

[Related Articles](#), [Links](#)

 Lactate dehydrogenase-C4 is involved in heparin- and NADH-dependent bovine sperm capacitation.  
Andrologia. 2002 Apr;34(2):91-7. Erratum in: Andrologia. 2002 Dec;34(6):405.  
PMID: 11966575 [PubMed - indexed for MEDLINE]

95: [Tendi EA, Bosetti F, Dasgupta SF, Stella AM, Drieu K, Rapoport](#) [SI.](#) [Related Articles](#), [Links](#)

 Ginkgo biloba extracts EGb 761 and bilobalide increase NADH dehydrogenase mRNA level and mitochondrial respiratory control ratio in PC12 cells.  
Neurochem Res. 2002 Apr;27(4):319-23.  
PMID: 11958534 [PubMed - indexed for MEDLINE]

96: [Cho N, Chueh PJ, Kim C, Caldwell S, Morre DM, Morre DJ.](#) [Related Articles](#), [Links](#)

 Monoclonal antibody to a cancer-specific and drug-responsive hydroquinone (NADH) oxidase from the sera of cancer patients.  
Cancer Immunol Immunother. 2002 May;51(3):121-9. Epub 2002 Feb 27.  
PMID: 11941450 [PubMed - indexed for MEDLINE]

97: [Kahn AM, Allen JC, Zhang S.](#) [Related Articles](#), [Links](#)

 Insulin increases NADH/NAD<sup>+</sup> redox state, which stimulates guanylate cyclase in vascular smooth muscle.  
Am J Hypertens. 2002 Mar;15(3):273-9.  
PMID: 11939620 [PubMed - indexed for MEDLINE]

98: [Kao MC, Di Bernardo S, Matsuno-Yagi A, Yagi T.](#) [Related Articles](#), [Links](#)

 Characterization of the membrane domain Nqo11 subunit of the proton-translocating NADH-quinone oxidoreductase of *Paracoccus denitrificans*.  
Biochemistry. 2002 Apr 2;41(13):4377-84.  
PMID: 11914084 [PubMed - indexed for MEDLINE]

99: [Barquera B, Hellwig P, Zhou W, Morgan JE, Hase CC, Gosink KK, Nilges M, Bruesehoff PJ, Roth A, Lancaster CR, Gennis RB.](#) [Related Articles](#), [Links](#)

 Purification and characterization of the recombinant Na<sup>+</sup>-translocating NADH:quinone oxidoreductase from *Vibrio cholerae*.  
Biochemistry. 2002 Mar 19;41(11):3781-9.  
PMID: 11888296 [PubMed - indexed for MEDLINE]

100: [Chueh PJ, Kim C, Cho N, Morre DM, Morre DJ.](#) [Related Articles](#), [Links](#)

 Molecular cloning and characterization of a tumor-associated, growth-related, and time-keeping hydroquinone (NADH) oxidase (tNOX) of the HeLa cell surface.  
Biochemistry. 2002 Mar 19;41(11):3732-41.  
PMID: 11888291 [PubMed - indexed for MEDLINE]

101: [MacDonald MJ, Kelley PC, Laclau M.](#) [Related Articles](#), [Links](#)  
 Histochemical evidence for pathways insulin cells use to oxidize glycolysis-derived NADH.  
Metabolism. 2002 Mar;51(3):318-21.  
PMID: 11887167 [PubMed - indexed for MEDLINE]

102: [Lemeshko VV.](#) [Related Articles](#), [Links](#)  
 Cytochrome c sorption-desorption effects on the external NADH oxidation by mitochondria: experimental and computational study.  
J Biol Chem. 2002 May 17;277(20):17751-7. Epub 2002 Mar 8.  
PMID: 11886867 [PubMed - indexed for MEDLINE]

103: [Bottcher B, Scheide D, Hesterberg M, Nagel-Steger L, Friedrich T.](#) [Related Articles](#), [Links](#)  
 A novel, enzymatically active conformation of the Escherichia coli NADH:ubiquinone oxidoreductase (complex I).  
J Biol Chem. 2002 May 17;277(20):17970-7. Epub 2002 Mar 5.  
PMID: 11880370 [PubMed - indexed for MEDLINE]

104: [Kim C, Crane FL, Faulk WP, Morre DJ.](#) [Related Articles](#), [Links](#)  
 Purification and characterization of a doxorubicin-inhibited NADH-quinone (NADH-ferricyanide) reductase from rat liver plasma membranes.  
J Biol Chem. 2002 May 10;277(19):16441-7. Epub 2002 Mar 1.  
PMID: 11875069 [PubMed - indexed for MEDLINE]

105: [Pantano S, Alber F, Lamba D, Carloni P.](#) [Related Articles](#), [Links](#)  
 NADH interactions with WT- and S94A-acyl carrier protein reductase from *Mycobacterium tuberculosis*: an ab initio study.  
Proteins. 2002 Apr 1;47(1):62-8.  
PMID: 11870865 [PubMed - indexed for MEDLINE]

106: [Janiszewski M, Souza HP, Liu X, Pedro MA, Zweier JL, Laurindo FR.](#) [Related Articles](#), [Links](#)  
 Overestimation of NADH-driven vascular oxidase activity due to lucigenin artifacts.  
Free Radic Biol Med. 2002 Mar 1;32(5):446-53.  
PMID: 11864784 [PubMed - indexed for MEDLINE]

107: [Fang J, Beattie DS.](#) [Related Articles](#), [Links](#)  
 Novel FMN-containing rotenone-insensitive NADH dehydrogenase from *Trypanosoma brucei* mitochondria: isolation and characterization.  
Biochemistry. 2002 Mar 5;41(9):3065-72.  
PMID: 11863445 [PubMed - indexed for MEDLINE]

108: [Nakashima Y, Shinzawa-Itoh K, Watanabe K, Naoki K, Hano N, Yoshikawa S.](#) [Related Articles](#), [Links](#)  
 Steady-state kinetics of NADH:coenzyme Q oxidoreductase isolated from bovine heart mitochondria.  
J Bioenerg Biomembr. 2002 Feb;34(1):11-9.  
PMID: 11860176 [PubMed - indexed for MEDLINE]

109: [Papa S, Sardanelli AM, Scacco S, Petruzzella V, Technikova-Dobrova Z, Vergari R, Signorile A.](#) [Related Articles](#), [Links](#)  
The NADH: ubiquinone oxidoreductase (complex I) of the mammalian

 respiratory chain and the cAMP cascade.  
J Bioenerg Biomembr. 2002 Feb;34(1):1-10. Review.  
PMID: 11860175 [PubMed - indexed for MEDLINE]

110: [Steuber J, Rufibach M, Fritz G, Neese F, Dimroth P.](#) [Related Articles](#), [Links](#)

 Inactivation of the Na<sup>+</sup>-translocating NADH:ubiquinone oxidoreductase from *Vibrio alginolyticus* by reactive oxygen species.  
Eur J Biochem. 2002 Feb;269(4):1287-92.  
PMID: 11856363 [PubMed - indexed for MEDLINE]

111: [Scheide D, Huber R, Friedrich T.](#) [Related Articles](#), [Links](#)

 The proton-pumping NADH:ubiquinone oxidoreductase (complex I) of *Aquifex aeolicus*.  
FEBS Lett. 2002 Feb 13;512(1-3):80-4.  
PMID: 11852056 [PubMed - indexed for MEDLINE]

112: [Voronina S, Sukhomlin T, Johnson PR, Erdemli G, Petersen OH, Tepikin A.](#) [Related Articles](#), [Links](#)

 Correlation of NADH and Ca<sup>2+</sup> signals in mouse pancreatic acinar cells.  
J Physiol. 2002 Feb 15;539(Pt 1):41-52.  
PMID: 11850500 [PubMed - indexed for MEDLINE]

113: [Zhang Q, Piston DW, Goodman RH.](#) [Related Articles](#), [Links](#)

 Regulation of corepressor function by nuclear NADH.  
Science. 2002 Mar 8;295(5561):1895-7. Epub 2002 Feb 14.  
PMID: 11847309 [PubMed - indexed for MEDLINE]

114: [Lancien M, Martin M, Hsieh MH, Leustek T, Goodman H, Coruzzi GM.](#) [Related Articles](#), [Links](#)

 *Arabidopsis glt1-T* mutant defines a role for NADH-GOGAT in the non-photore respiratory ammonium assimilatory pathway.  
Plant J. 2002 Feb;29(3):347-58.  
PMID: 11844111 [PubMed - indexed for MEDLINE]

115: [Joet T, Cournac L, Peltier G, Havaux M.](#) [Related Articles](#), [Links](#)

 Cyclic electron flow around photosystem I in C(3) plants. In vivo control by the redox state of chloroplasts and involvement of the NADH-dehydrogenase complex.  
Plant Physiol. 2002 Feb;128(2):760-9.  
PMID: 11842179 [PubMed - indexed for MEDLINE]

116: [Ammendola R, Ruocchio MR, Chirico G, Russo L, De Felice C, Esposito F, Russo T, Cimino F.](#) [Related Articles](#), [Links](#)

 Inhibition of NADH/NADPH oxidase affects signal transduction by growth factor receptors in normal fibroblasts.  
Arch Biochem Biophys. 2002 Jan 15;397(2):253-7.  
PMID: 11795879 [PubMed - indexed for MEDLINE]

117: [Reynolds CM, Meyer J, Poole LB.](#) [Related Articles](#), [Links](#)

 An NADH-dependent bacterial thioredoxin reductase-like protein in conjunction with a glutaredoxin homologue form a unique peroxiredoxin (AhpC) reducing system in *Clostridium pasteurianum*.  
Biochemistry. 2002 Feb 12;41(6):1990-2001.  
PMID: 11827546 [PubMed - indexed for MEDLINE]

118: [Morre DJ, Lawler J, Wang S, Keenan TW, Morre DM.](#) [Related Articles](#), [Links](#)

 Entrainment in solution of an oscillating NADH oxidase activity from the bovine milk fat globule membrane with a temperature-compensated period length suggestive of an ultradian time-keeping (clock) function. *Biochim Biophys Acta*. 2002 Feb 10;1559(1):10-20. PMID: 11825584 [PubMed - indexed for MEDLINE]

119: [Kim YK, Lee MS, Son SM, Kim IJ, Lee WS, Rhim BY, Hong KW, Kim CD.](#) [Related Articles](#), [Links](#)

 Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. *Diabetes*. 2002 Feb;51(2):522-7. PMID: 11812764 [PubMed - indexed for MEDLINE]

120: [Cook SA, Shiemke AK.](#) [Related Articles](#), [Links](#)

 Evidence that a type-2 NADH:quinone oxidoreductase mediates electron transfer to particulate methane monooxygenase in *methylococcus capsulatus*. *Arch Biochem Biophys*. 2002 Feb 1;398(1):32-40. PMID: 11811946 [PubMed - indexed for MEDLINE]

121: [Higuchi T, Takeda Y, Hashimoto M, Nagano O, Hirakawa M.](#) [Related Articles](#), [Links](#)

 Dynamic changes in cortical NADH fluorescence and direct current potential in rat focal ischemia: relationship between propagation of recurrent depolarization and growth of the ischemic core. *J Cereb Blood Flow Metab*. 2002 Jan;22(1):71-9. PMID: 11807396 [PubMed - indexed for MEDLINE]

122: [Fontaine L, Meynil-Salles I, Girbal L, Yang X, Croux C, Soucaille P.](#) [Related Articles](#), [Links](#)

 Molecular characterization and transcriptional analysis of *adhE2*, the gene encoding the NADH-dependent aldehyde/alcohol dehydrogenase responsible for butanol production in alcohologenic cultures of *Clostridium acetobutylicum* ATCC 824. *J Bacteriol*. 2002 Feb;184(3):821-30. PMID: 11790753 [PubMed - indexed for MEDLINE]

123: [Didion SP, Faraci FM.](#) [Related Articles](#), [Links](#)

 Effects of NADH and NADPH on superoxide levels and cerebral vascular tone. *Am J Physiol Heart Circ Physiol*. 2002 Feb;282(2):H688-95. PMID: 11788419 [PubMed - indexed for MEDLINE]

124: [Nakamaru-Ogiso E, Yano T, Ohnishi T, Yagi T.](#) [Related Articles](#), [Links](#)

 Characterization of the iron-sulfur cluster coordinated by a cysteine cluster motif (CXXCXXXCX27C) in the Nqo3 subunit in the proton-translocating NADH-quinone oxidoreductase (NDH-1) of *Thermus thermophilus* HB-8. *J Biol Chem*. 2002 Jan 18;277(3):1680-8. Epub 2001 Nov 9. PMID: 11704668 [PubMed - indexed for MEDLINE]

Display [Summary](#)

Show [200](#)

Sort by

Send to

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)  
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Sep 5 2006 08:10:00